[(' All 17,000 samples were genotyped with the GeneChip 500K Mapping Array Set (Affymetrix chip), which comprises 500,568 SNPs, as described in Methods.', {'entities': [(77, 92, 'Affymetrix assay')]}),
 ('SGENE was initially made up of 1,321 cases and 12,277 controls typed at deCODE Genetics using the Illumina HumanHap300 BeadChip.', {'entities': [(98, 127, 'Illumina assay')]}),
 ('The Center for Inherited Disease Research (CIDR) genotyped samples using the Illumina Human610-Quad v.', {'entities': []}),
 (' All genotyping was performed on the Illumina Hap550 array and Illumina Quad-610 at the Genome Institute of Singapore.', {'entities': [(37, 58, 'Illumina assay')]}),
 (' The genomic DNA (250 ng/5ul) samples were processed according to standard Affymetrix procedures for processing of the Affymetrix 6.0 GeneChip assay.', {'entities': []}),
 ('As part of GENEVA, DNA samples were genotyped on the Illumina Human 1M-Duo beadchip by the Center for Inherited Disease Research (CIDR) at Johns Hopkins University.', {'entities': [(53, 83, 'Illumina assay')]}),
 ('5% between Sequenom and Affymetrix 6.0 genotyping.', {'entities': []}),
 (' Briefly, Illumina HumanHap 550K and 510S BeadChips were used for genotyping of DNA samples from all of the LCLs in the Genotype Shared Resource at Mayo Clinic.', {'entities': [(10, 51, 'Illumina assay')]}),
 (' Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(36, 78, 'Affymetrix assay')]}),
 (' Genotypes were called using the Illumina BeadStudio 3.1 software package using previously generated cluster positions generated by Illumina.', {'entities': []}),
 (' After checking DNA quality, 1225 individuals were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(71, 113, 'Affymetrix assay')]}),
 (' Genotyping data for the top 44 SNPs were obtained from the Illumina HumanHap 660k and 610k BeadChips in the MDACC study.', {'entities': [(60, 101, 'Illumina assay')]}),
 ('Genotyping in the SHARe study (,) was carried out using the Affymetrix (Santa Clara, CA, USA) GeneChip Human Mapping 500K mapping array and supplemental 50K mapping array (HuGeneFocused50K) with gene-centric and coding SNPs.', {'entities': [(60, 135, 'Affymetrix assay')]}),
 (' The European-American discovery cohort and the African-American replication cohort were genotyped on the Illumina Human 1M beadchip and the Australian cohort was genotyped on the Illumina CNV370v1 beadchip.', {'entities': [(106, 132, 'Illumina assay')]}),
 (' For CCFR phase II, samples were genotyped using the Illumina 1M Omni.', {'entities': []}),
 ('Genotyping was done in each cohort separately using high-density SNP marker platforms (ARIC—Affymetrix 6.0, CHS—Illumina 370, FHS—Affymetrix 500K, RS—Illumina Infinium HumanHap550) and then imputed to ∼2.', {'entities': [(130, 145, 'Affymetrix assay')]}),
 (' Principal components were generated using EIGENSTRAT () with the curated CARe African-American Affymetrix 6.0 genotype data combined with 1178 European Americans (EA) (a multiple sclerosis GWAS graciously offered by Dr Phil de Jager and colleagues) and from 756 Nigerians from the Yoruba region (an hypertension GWAS graciously offered by Dr Richard Cooper and colleagues).', {'entities': []}),
 (' Using the software Tagger as implemented in Haploview (,) and data from the CEPH population in the International HapMap project, release 2 (,), we designed a panel of 4905 SNPs that were compatible with the Illumina Infinium technology, of which 4650 SNPs remained for analysis following clustering quality control.', {'entities': []}),
 (' We genotyped stage 2 replication samples with (i) the Illumina 317K array at the Feinstein Institute (for the NARAC-III samples; unpublished data); (ii) using the kinetic PCR platform at Celera Diagnostics (for the GCI and LUMC samples); and (iii) with the Sequenom iPlex platform at the Broad Institute (for the EIRA-II and AMC/UVA samples).', {'entities': [(55, 184, 'Illumina assay')]}),
 (' We selected autosomal SNPs >100 kb apart and present on the Illumina CNV370 beadchip (a full list of SNPs is available upon request).', {'entities': [(61, 85, 'Illumina assay')]}),
 (' Once acceptable genotyping standards were met, Affymetrix genotypes were compared with previously produced Taqman, Illumina, and/or Perlegen genotypes at a mean of 85 (range, 10–142) sites per sample.', {'entities': []}),
 ('All genotyping in the GABRIEL studies were carried out at Centre National de Génotypage (Evry, France) using the Illumina Human610 Quad BeadChip (Illumina, Inc.', {'entities': [(113, 144, 'Illumina assay')]}),
 (' On the Illumina Human-1 Genotyping BeadChip about 109,000 exon-centric SNPs can be interrogated.', {'entities': [(8, 44, 'Illumina assay')]}),
 (' Illumina provides information on which 1M BeadChip SNPs were located within known common CNV-regions.', {'entities': [(1, 51, 'Illumina assay')]}),
 (' The Spearman correlation coefficient between genotype calls obtained from the Affymetrix_®  chip and iPLEX platform for these three markers ranged from 0.96 to 0.', {'entities': [(79, 97, 'Affymetrix assay')]}),
 (' Participants in the venous thromboembolism study were genotyped with the Illumina Human660W-Quad platform.', {'entities': [(74, 106, 'Illumina assay')]}),
 ('Genotyping was conducted at Perlegen Sciences using their 600K genotyping platform, which comprises approximately 600,000 tagging SNPs designed to be in high linkage disequilibrium with untyped SNPs for the three HapMap populations.', {'entities': []}),
 (' For the Illumina Infinium platform, in addition to the four CEPH controls included in each 96-well plate provided by the genotyping service provider, 15 out of 585 samples were genotyped twice.', {'entities': [(9, 35, 'Illumina assay')]}),
 (' We identified a set of SNP markers common to both the Illumina 610Q platform and the HumanHap 550 platform as our genotype set.', {'entities': [(55, 77, 'Illumina assay')]}),
 ('Genotyping for all GoKinD subjects was conducted on the Affymetrix 5.0 platform.', {'entities': [(56, 79, 'Affymetrix assay')]}),
 (' 1,968 and 35,382 Icelandic case- and control-samples respectively, were successfully assayed with the Infinium HumanHap300 SNP chip (Illumina, SanDiego, CA, USA), containing 317,503 haplotype tagging SNPs derived from phase I of the International HapMap project.', {'entities': []}),
 (' The intensity data generated was loaded into Illumina’s Genome studio and genotypes were generated using a GenCall threshold of 0.15.', {'entities': []}),
 (' Subjects from CPSII, EPIC, MEC, PLCO and PBCS were genotyped using the Illumina Human 660k-Quad SNP array (Illumina, Inc.', {'entities': [(72, 106, 'Illumina assay')]}),
 ('DNA samples from 9,274 Framingham Heart Study three generation participants were genotyped using the Affymetrix 500K mapping array and the Affymetrix 50K supplemental array.', {'entities': [(101, 130, 'Affymetrix assay')]}),
 (' In order to assess the association for the SNP rs4962416 on 10q26, which is in the CEU section of the Hapmap database but absent from the Illumina Hap300 chip, we use a method based on haplotypes of two markers (rs7077275 and rs893856) present on the chip.', {'entities': [(139, 159, 'Illumina assay')]}),
 ('       A genome-wide association study for LDL-C was carried out in 2346 people of the Island of Kosrae, Federated States of Micronesia using SNPs from the Affymetrix 500k platform.', {'entities': [(156, 180, 'Affymetrix assay')]}),
 (' To address case-control stratification we used identity-by-state to cluster EIRA cases and controls on the basis of on Illumina 317K SNP data into 165 substrata, and then to cluster NARAC cases and controls similarly on the basis of Illumina 550K SNP data into 396 substrata.', {'entities': [(120, 133, 'Illumina assay')]}),
 ('A list of 76,534 common SNPs across Illumina 550/610/1M and Affymetrix 5.0/6.', {'entities': []}),
 (' A total of 137 cases which passed the DNA quality check were entered into the GWAS using Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(90, 132, 'Affymetrix assay')]}),
 (' In stage 1, samples from the patients and the Canadian controls were genotyped for 373,400 single-nucleotide polymorphisms (SNPs) with the use of the Illumina HumanHap370 BeadChip.', {'entities': [(151, 180, 'Illumina assay')]}),
 (' Genotyping for participants in the Wellcome Trust Case Control Consortium study was performed as reported, using the Affymetrix 500K Mapping Array sets.', {'entities': [(118, 147, 'Affymetrix assay')]}),
 (' For controls we made use of controls from the CGEMS studies of breast and prostate cancers which were genotyped using Illumina HumanHap550 and Phase 1A HumanHap300+Phase 1BHumanHap240 Beadchips respectively (,).', {'entities': [(119, 194, 'Illumina assay')]}),
 (' The risk SNP BD11934905 () is not on the Illumina 660W array and was not genotyped in this study.', {'entities': [(42, 61, 'Illumina assay')]}),
 (' SNPs on the Y\xa0chromosome and Affymetrix quality-control (QC) probes were excluded from analysis (n = 3,280).', {'entities': []}),
 (' The final sample included 1606 cases (1302 were genotyped at Affymetrix) and 1794 control subjects (1001 were genotyped at Affymetrix).', {'entities': []}),
 ('  Different discovery cohorts used different genotyping platforms: Illumina 370CNV for AGES-Reykjavik, AffymetrixHuman 500K and gene-centric 50K for FHS, Illumina 550K version 3 for RS I and II, and Affymetrix 6.0 for GENOA.', {'entities': [(154, 167, 'Illumina assay')]}),
 (' An overlapping set of 4830 controls were also genotyped on the Illumina 1.2M chip as part of a separate WTCCC2 project, and the 50,000 SNPs which are shared between that platform and the Affymetrix 6.', {'entities': [(64, 179, 'Illumina assay')]}),
 ('01 for the gene-based test in the CSSCD dataset based on the following consideration: the average number of SNPs per gene in the Illumina 610 array is 25, so that a P  value less than .', {'entities': [(129, 147, 'Illumina assay')]}),
 (' Genotyping was conducted on 9,274 Framingham Heart Study participants using the Affymetrix 500K mapping array and the Affymetrix 50K gene-focused molecular imprinted polymer array (SNP Health Association Resource at http://www.', {'entities': [(81, 110, 'Affymetrix assay')]}),
 (' FHS samples were genotyped using the Affymetrix 500K and MIPS 50K SNPs.', {'entities': [(38, 53, 'Affymetrix assay')]}),
 (' Individuals were genotyped on the Illumina HumanHap500 version 3 BeadChip.', {'entities': [(35, 74, 'Illumina assay')]}),
 (' Genotyping was performed using Illumina Human1Mv1_C BeadChips and the Illumina Infinium II assay protocol ().', {'entities': [(32, 62, 'Illumina assay')]}),
 ('Genotypes were generated by the Johns Hopkins University SNP Center at the Center for Inherited Disease Research (CIDR) for 665,352 polymorphic tagging SNPs using Illumina HumanHap650Y Versions 1 and 3 BeadChips and the Illumina Infinium II assay protocol .', {'entities': [(163, 211, 'Illumina assay')]}),
 (' Gene expression was assayed using standard Affymetrix procedures on samples from 9 different brain regions (prefrontal cortex, cerebral cortex, thalamus, visual cortex, hippocampus, amygdala, caudate, putamen and cerebellum) of 4 individuals (1 each male alcoholic, female alcoholic, male control, female control), obtained from the NIAAA-supported brain bank at the Tissue Resource Center located in the Neuropathology Unit of the Department of Pathology, University of Sydney, Australia.', {'entities': []}),
 ('Nine hundred and seventy-two case samples, including 841 self-identifying as ‘white’, were genotyped on the Illumina HumanHap 650Y product at Rosetta Inpharmatics.', {'entities': []}),
 ('  DNA was genotyped with the Illumina Human610-Quad BeadChip, and 514,073 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with 34 European reference populations.', {'entities': [(29, 60, 'Illumina assay')]}),
 (' Genome-wide genotyping was performed using the Affymetrix_®  Genome-Wide Human SNP Array 6.0.', {'entities': [(48, 93, 'Affymetrix assay')]}),
 (' DNA from each individual was genotyped on the Affymetrix GeneChip 6.0 platform as a part of a case-control multiple sclerosis meta-analysis ().', {'entities': [(47, 79, 'Affymetrix assay')]}),
 (' Both cohorts were genotyped using Affymetrix GeneChip Mapping 500K Array.', {'entities': [(35, 73, 'Affymetrix assay')]}),
 (' The images were captured using Affymetrix GeneChip Scanner 3000. We normalized data to allow for array-to-array comparisons, and we detected differences between groups in GeneSpring with significance at the 0.', {'entities': [(32, 103, 'Affymetrix assay')]}),
 (' Genotyping was done with the Illumina 550K array (Illumina, San Diego, CA, USA) in self-reported Caucasian individuals.', {'entities': [(30, 49, 'Illumina assay')]}),
 ('The GWAS genotyping of the Spanish SSc and controls together with Dutch and German SSc patients was performed at the Department of Medical Genetics of the University Medical Center Utrecht (The Netherlands) using the commercial release Illumina human CNV370K BeadChip that contains 300.000 standard SNPs with an additional 52,167 markers designed to specifically target nearly 14,000 copy number variant (CNV) regions of the genome, for a total of over 370,000 markers.', {'entities': [(236, 267, 'Illumina assay')]}),
 (" Genotyping for the replication phase 1 series was obtained from GWAS of lung cancer risk using Illumina's HumanHap300 BeadChip ().", {'entities': [(96, 127, 'Illumina assay')]}),
 (' The same platform (Affymetrix Genome-Wide Human SNP Array 5.0) was used for the whole-genome scan of the controls.', {'entities': [(20, 62, 'Affymetrix assay')]}),
 (' on Affymetrix platforms in case of KORA F3 and KORA F4, and on Illumina platforms in case of MICROS, InCHIANTI and CROATIA-VIS.', {'entities': [(64, 82, 'Illumina assay'), (4, 24, 'Affymetrix assay')]}),
 (' We performed high-density genotyping using the Affymetrix 6.0 chips on 1276 cases and 715 controls following the recommended protocol, with genotype calling using the Birdseed program in APT BirdSuite 1.', {'entities': [(48, 68, 'Affymetrix assay')]}),
 (' Briefly, samples were genotyped and analysed using the Affymetrix Genome-Wide Human 6.0 array (Santa Clara, CA, USA) and the Birdseed calling algorithm.', {'entities': [(56, 94, 'Affymetrix assay')]}),
 (' Genotyping was performed using the Affymetrix 500K Gene Chip for KORA S3 and Affymetrix 6.0 for KORA S4.', {'entities': [(36, 61, 'Affymetrix assay')]}),
 (' DNA was genotyped on the Affymetrix 6.0 array as previously reported (, ), and 597,198 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with HapMap 3 reference populations.', {'entities': [(26, 46, 'Affymetrix assay')]}),
 ('0 for ARIC, Illumina 370CNV for CHS, Affymetrix 500K and 50K for FHS, and Illumina 550K v3 for RS.', {'entities': [(74, 87, 'Illumina assay'), (37, 52, 'Affymetrix assay')]}),
 (' The Illumina HumanHap550 (v.', {'entities': []}),
 (' In the EDIC cohort, subjects were genotyped on the Illumina HumanHap550 composed of ∼550 000 SNPs.', {'entities': []}),
 (' Controls were genotyped using the Affymetrix 6.0 array, at the Broad Institute National Center for Genotyping and Analysis.', {'entities': [(35, 55, 'Affymetrix assay')]}),
 (' A subset of these individuals was genotyped using the Affymetrix 6.0 GeneChip Array (Affymetrix, Inc.', {'entities': [(55, 84, 'Affymetrix assay')]}),
 ("DNAs from BA patients and control individuals were genotyped using the Affymetrix  Genome-Wide Human SNP Array 5.0 and the Affymetrix  GeneChip Human Mapping 500 K Array Set (250 K Nsp I and Sty I arrays), respectively, according to the manufacturer's protocol.", {'entities': [(71, 114, 'Affymetrix assay')]}),
 ('1) SNP Beadchip was used to obtain genotypes for the CGEMS breast cancer controls, and the Illumina HumanHap250S (v1.0) and HumanHap300 (v1.', {'entities': []}),
 (' All SNPs with borderline significant associations underwent additional quality control checks including:\n\n visual inspection of genotype clusters; verification of genotype concordance between HapMap samples genotyped by Illumina on the Human1M and Human1M-Duo and with HapMap phase II release 24; verification of no major MAF difference in controls genotyped on the Human1M and Human1M-Duo.', {'entities': []}),
 (' All AD cases and 955 controls were genotyped at the Sanger Institute on the Illumina 610-quad chip.', {'entities': [(77, 99, 'Illumina assay')]}),
 (' Cross-platform comparison showed CHIAMO to outperform BRLMM (the standard Affymetrix algorithm) by having an error rate under 0.2% (), and comparison of 10_8  duplicate genotypes in our study gave a discordance rate of 0.', {'entities': []}),
 (' To confirm ancestries, we combined our 189 sample genotypes with 30 HapMap reference samples [] were also genotyped on Affymetrix 500K arrays, including 10 individuals from each of the following populations: Yoruba in Ibadan, Nigeria; Japanese in Tokyo, Japan, and Chinese in Beijing, China; and Utah residents with ancestry from northern and western Europe.', {'entities': [(120, 142, 'Affymetrix assay')]}),
 (', San Diego, CA)[], except for the MAGICS/ISAAC data set (Illumina HumanHap300 BeadChip, thus contributing with 300K SNPs in the analysis).', {'entities': [(58, 87, 'Illumina assay')]}),
 ('_,   Gene expression data were analyzed by using the Affymetrix MAS5.0 algorithm.', {'entities': []}),
 ('  Genotyping was performed using the Affymetrix 6.0 array and genotypes were called using the Birdsees software.', {'entities': [(37, 57, 'Affymetrix assay')]}),
 (' Genotyping with the Affymetrix Mapping 250K Nsp and Affymetrix Mapping 250K Sty arrays was performed at the Vanderbilt Microarray Shared Resource at Vanderbilt University Medical Center, Nashville, TN, USA, using the standard protocol recommended by the manufacturer.', {'entities': [(21, 87, 'Affymetrix assay')]}),
 ('”   Genotyping was carried out at 2 different centres (The Wellcome Trust Sanger Centre, Cambridge, UK and Laboratory Corporation of America, Burlington, NC) using the Illumina Human550 quad array (Illumina, Inc.', {'entities': [(168, 196, 'Illumina assay')]}),
 (' Monocytes RNA profiles were generated using Illumina Human HT-12 expression V3 BeadChips.', {'entities': [(45, 89, 'Illumina assay')]}),
 (' GWAS genotyping, using the Illumina 370K array, was performed on a total of 6852 individuals selected from the BIGSIB and EDAC series (including N=336 parents); from a subsample of the NAG families that had previously been selected for 10cM microsatellite scans (), and a smaller number of additional alcohol dependent cases and controls from Cohorts 1 and 2. Additional GWAS data are included here for sample members who had been genotyped for other projects ().', {'entities': [(28, 47, 'Illumina assay')]}),
 (' DNA was genotyped with the Illumina Human660W-Quad BeadChip, and 494,082 SNPs passed quality control filters (sample call rate > 98%, SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with Hapmap European reference populations; 599 individuals were removed as genetic outliers based on PCA of an allele-sharing distance matrix.', {'entities': [(28, 60, 'Illumina assay')]}),
 ('Genotyping was performed using Illumina platforms (HumanHap 550 V3 for the ECLIPSE cohort and the HumanHap 550 [V1, V3, and Duo] for the Norway GenKOLS cohort; Illumina, Inc.', {'entities': [(31, 49, 'Illumina assay')]}),
 ('  All adolescents (n  = 602) were genotyped with the Illumina Human610-Quad BeadChip (Illumina, Inc.', {'entities': [(53, 84, 'Illumina assay')]}),
 (" Gender of 550 isolated, non-syndromic cleft palate (CP) cases in the international consortium study by recruitment siteThe Center for Inherited Disease Research (CIDR) genotyped DNA samples using Illumina's 610Quad platform and 99.1% passed CIDR quality control (QC) [].", {'entities': [(197, 224, 'Illumina assay')]}),
 ("Genotyping in the discovery sample was performed on Illumina Human-1 Genotyping 100k BeadChips (109\u2009000 SNPs selected with an exon-centric focus) and Illumina HumanHap300-Duo Genotyping BeadChips (318\u2009000 tag SNPs) (Illumina, San Diego, CA, USA) according to the manufacturer's standard protocols.", {'entities': [(52, 94, 'Illumina assay')]}),
 (' Meta-analyses of study-specific results were conducted separately for the Affymetrix 6.0 and the IBC chips using inverse-variance weighted fixed-effect models implemented in METAL ().', {'entities': [(75, 107, 'Affymetrix assay')]}),
 ('  Genotyping was performed using the Illumina 370CNV BeadChip system on 3,980 Cardiovascular Health Study (CHS) participants who were free of cardiovascular disease at baseline.', {'entities': [(37, 61, 'Illumina assay')]}),
 ('As all studies utilized compatible Illumina platforms, we combined 266,047 (258,137 autosomal and 7,910 X chromosome) SNPs passing QC in all three studies.', {'entities': [(35, 53, 'Illumina assay')]}),
 ('  Individuals were genotyped on the Illumina Human610 Genotyping Beadchip (, ).', {'entities': [(36, 73, 'Illumina assay')]}),
 (' AGES-Reykjavik genotyping was conducted with the Illumina 370CNV BeadChip array on 3664 participants.', {'entities': [(50, 74, 'Illumina assay')]}),
 ('html), adapted for Affymetrix 6.0 SNP data.', {'entities': []}),
 (' Cells were collected at days 3, 5, 7, 9 and 10 in three biological replicates and gene expression was assayed using Illumina human WGv3.0 microarrays.', {'entities': [(117, 150, 'Illumina assay')]}),
 ('  As there is only moderate overlap between the Illumina 550/610 arrays (used in the GERAD1 and NIA-LOAD GWAS) and the Illumina Omni1-Quad array (used in the ADRC GWAS) unobserved genotypes were imputed.', {'entities': [(48, 71, 'Illumina assay')]}),
 (' The Illumina 1M –Duo array has a total of 1,072,820 probes, of which 23,812 are “intensity-only,” leaving 1,049,008 probes as SNP assays.', {'entities': [(5, 27, 'Illumina assay')]}),
 (' The Illumina Human610-Quadv1_B BeadChip (Illumina, Inc.', {'entities': [(5, 40, 'Illumina assay')]}),
 (' We also assessed the frequency of these rare CNVs in a set of population-based controls, which were genotyped for another study using the Illumina 370K SNP array.', {'entities': [(139, 162, 'Illumina assay')]}),
 (' Hybridization probes were prepared with precautions to avoid contamination, as described (Affymetrix Assay 6.0, []).', {'entities': []}),
 (' The BRLMM algorithm from Affymetrix was used to make genotype calls, and the average genotyping call rate was 99.1%.', {'entities': []}),
 (' A total of 331918 SNPs (common in both the Illumina HumanHap 370k and 610k BeadChips) of 377 case-control pairs were used in the analysis.', {'entities': [(44, 85, 'Illumina assay')]}),
 ('For the Texas lung cancer GWAS, genotyping procedures of Illumina HumanHap300 v1.1 BeadChips (Illumina, San Diego, CA) with genomic DNA and quality control have been described elsewhere ().', {'entities': [(57, 92, 'Illumina assay')]}),
 ('We conducted a meta-analysis of genome-wide data in 1658 women genotyped with the HumanHap500 as part of the Cancer Genetic Markers of Susceptibility Project (CGEMS) and in 1682 women genotyped with the Affymetrix 500K mapping array and the Affymetrix 50K Supplementary array as a part of the SNP Health Association Resource (SHARe data set, part of NHLBI FHS) to identify novel loci that influence plasma one-carbon metabolite levels.', {'entities': [(203, 232, 'Affymetrix assay')]}),
 ('Studies used Illumina genotyping arrays for genome wide genotyping: Illumina Infinium HD Human610-Quad BeadChip in Health 2000 (H2000), Illumina HumanCNV370-Duo BeadChip in the Northern Finland Birth Cohort 1966 (NFBC1966), and Illumina Human670K custom BeadChip in the Cardiovascular Risk in Young Finns Study (YFS) and the Helsinki Birth Cohort Study (HBCS).', {'entities': [(13, 111, 'Illumina assay')]}),
 ("All 10 DNA pools were genotyped in duplicate using the Affymetrix Genome-Wide Human SNP Array 6.0 according to the manufacturer's protocol.", {'entities': [(55, 97, 'Affymetrix assay')]}),
 ('5) from the Illumina 1M array, respectively.', {'entities': [(12, 29, 'Illumina assay')]}),
 (' Biotinylated cRNA was applied to Illumina HumanWG-6 v1 Expression BeadChips and hybridized overnight at 58°C.', {'entities': [(34, 76, 'Illumina assay')]}),
 (' As there is only moderate overlap between the Illumina 550/610 arrays (used in the GERAD1 and NIA-LOAD GWAS) and the Illumina Omni1-Quad array (used in the ADRC GWAS) unobserved genotypes were imputed.', {'entities': [(47, 70, 'Illumina assay')]}),
 (' DNA was extracted from blood, and genotyping was performed with the Illumina 610-Quad\nBeadChip system (Illumina Inc.', {'entities': []}),
 (' Plots and corresponding inflation values are shown for both normalization methodsThirty-six SNPs from the Illumina HuHap550 array were genotyped individually using the Sequenom MassArray Genotyping platform (Sequenom Inc, San Diego, CA) on all case and control samples used in the pooling GWAS.', {'entities': [(107, 207, 'Illumina assay')]}),
 ('The University of Pittsburgh ADRC sample of 1,440 AD cases was genotyped using the Illumina Omni1-Quad chip (containing probes for 1,016,423 SNPs and/or copy-number variations) at the Feinstein Institute of Medical Research (Manhasset, NY).', {'entities': [(83, 107, 'Illumina assay')]}),
 (") and Illumina's genotyping software Bead Studio 2.0 (Illumina Inc.", {'entities': []}),
 (' Samples from self-described European whites were genotyped at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University using the Illumina Omni1 Quad platform.', {'entities': [(150, 178, 'Illumina assay')]}),
 ('Gene expression levels were quantified using mRNA derived from peripheral blood mononuclear cells (PBMCs) of 228 subjects of European ancestry with Relapsing Remitting (RR) Multiple Sclerosis (MS) using an Affymetrix Human Genome U133 Plus 2.0.', {'entities': []}),
 (' The Illumina BeadStudio 3.2 software was used to generate SNP genotypes from bead intensity data.', {'entities': []}),
 (' GWAS of the JHH case population was performed using the Illumina 610K chip ().', {'entities': [(57, 75, 'Illumina assay')]}),
 (' We also obtained publicly available Affymetrix SNP Array 6.0 Chip SNP data for the same cell lines, which involved 643,600 SNPs unique to the Affymetrix SNP array.', {'entities': [(37, 66, 'Affymetrix assay')]}),
 (' DNA samples were collected in accordance with standard protocols and submitted to different genotype centres using different SNP platforms (Illumina 317K, Illumina HumanCNV370-Quadv3, Illumina Human610-Quad, and Affymetrix 6.0).', {'entities': [(141, 154, 'Illumina assay')]}),
 ('The consortium was formed after the individual studies had finalized their GWAS platforms, and the 6 studies included used different platforms: the Illumina Human 370-Duo BeadChip® for AGES-Reykjavik Study; the Affymetrix GeneChip SNP Array 6.0® for ARIC; the Illumina Human610-Quad BeadChip® for ASPS; the Affymetrix GeneChip Human Mapping 500K Array Set® and 50K Human Gene Focused Panel® for FHS; and the Illumina HumanHap550 Duo BeadChip® for the Rotterdam Study.', {'entities': [(148, 179, 'Illumina assay'), (211, 244, 'Affymetrix assay')]}),
 (' Different discovery cohorts used different genotyping platforms: Illumina 370CNV for AGES-Reykjavik, AffymetrixHuman 500K and gene-centric 50K for FHS, Illumina 550K version 3 for RS I and II, and Affymetrix 6.0 for GENOA.', {'entities': [(153, 166, 'Illumina assay')]}),
 (' A subset of these records is linked to eMERGE-supported Illumina 660W-Quad genotyping, and the results of the PR analysis are presented here.', {'entities': [(57, 70, 'Illumina assay')]}),
 (' Genome-wide genotyping in the FHS was performed on the Affymetrix GeneChip Human Mapping 500K Array Set® and 50K Human Gene Focused Panel®.', {'entities': [(56, 100, 'Affymetrix assay')]}),
 (' In total, 352 samples from the Saami subjects were genotyped with the Affymetrix 100\u2009K array.', {'entities': [(71, 93, 'Affymetrix assay')]}),
 (' Replication Cohort #2For the genome-wide association study, approximately 750ng of genomic DNA was used to genotype each sample on the Illumina HumanHap300 Genotyping BeadChip (Illumina, San Diego) at the Feinstein Institute for Medical Research.', {'entities': [(136, 176, 'Illumina assay')]}),
 (' Baseline characteristics of studies included in the GWAS meta-analysis of OA-phenotypes GWA = genome-wide association; OA = osteoarthritis; NA = not applicable/availableGWAS Rotterdam Study (discovery study): genotyping of the samples with the Illumina HumanHap550v3 Genotyping BeadChip was carried out at the Genetic Laboratory of the Department of Internal Medicine of Erasmus Medical Center, Rotterdam, the Netherlands.', {'entities': [(245, 287, 'Illumina assay')]}),
 (' Extracted RNA was quality checked on the Agilent 2100 Bioanalyser, subjected to two rounds of linear amplification and hybridised to Illumina MouseRef-8 v1.0 Expression BeadChips according to the manufacturer’s protocol (see also ).', {'entities': [(134, 179, 'Illumina assay')]}),
 (' The Sorbs were assayed with the 500K Affymetrix GeneChip (250K Sty and 250K Nsp arrays, Affymetrix, Inc, n  = 526) and Affymetrix Genome-Wide Human SNP Array 6.0 (n  = 494) at the Microarray Core Facility of the Interdisciplinary Centre for Clinical Research, University of Leipzig, Germany and ATLAS Biolabs GmbH, Berlin, Germany.', {'entities': [(38, 162, 'Affymetrix assay')]}),
 (' The primary scan for the discovery population of RCC case–control study (910 cases and 566 controls) was performed at MD Anderson Cancer Center using the Illumina HumanHap660W Beadchips.', {'entities': [(155, 186, 'Illumina assay')]}),
 (' General population controls were obtained using the Illumina iControlDB client to download genotypes for 3,294 Caucasian individuals with genotype data available from any of the three available HumanHap550k products (v1, v3, and −2v3).', {'entities': []}),
 (' SNPs were genotyped with an Illumina BeadStation 500G and with a Sequenom MassArray matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (Sequenom, Inc, San Diego, Calif).', {'entities': [(29, 84, 'Illumina assay')]}),
 ('Since the genotype data were not generated from a single Illumina Beadarray platform (two for SCORM and three for SP2), we analyzed all common markers in the dataset(s) tested.', {'entities': [(57, 84, 'Illumina assay')]}),
 (' The ARIC cohort did not have imputed data on those of African ancestry so testing was restricted to successfully genotyped SNPs on their Affymetrix 6.0 chip that had an average weighted MAF of at least 0.', {'entities': [(138, 157, 'Affymetrix assay')]}),
 (' As both KARE (stage I) and KIOM (stage II) data sets were genotyped using the same Affymetrix SNP 5.0 array platform, the two SNP data sets were combined to a data set of 9937 individuals in the joint analysis.', {'entities': [(84, 108, 'Affymetrix assay')]}),
 (' Genotypes were determined by the RIKEN Center for Genomic Medicine with the Illumina Human610-Quad BeadChip platform (Illumina, San Diego, CA).', {'entities': [(77, 117, 'Illumina assay')]}),
 ('Genome-wide genotyping of the InCHIANTI and BLSA was assessed using the Illumina Infinium HumanHap 550K.', {'entities': []}),
 (' The first phase involved genotyping through ServiceXS in Leiden, The Netherlands, using the Illumina HumanHap300 BeadChip version 2 duo array (with 317k tagging SNPs).', {'entities': [(93, 122, 'Illumina assay')]}),
 ("A total of 90 white TESI cases and 90 gender, race and ethnicity matched controls were genotyped the Illumina Beadstation 500 according to manufacturer's recommended protocol.", {'entities': []}),
 (' Genotyping was conducted using the Illumina 550K array.', {'entities': [(36, 55, 'Illumina assay')]}),
 (' Individual genotype data were extracted from the genome-wide Illumina 660 Quad Array.', {'entities': [(62, 85, 'Illumina assay')]}),
 (' The genotyping was performed using Illumina HumanHap 670k custom arrays, and genotypes were clustered using the Illuminus algorithm.', {'entities': [(36, 72, 'Illumina assay')]}),
 (' To check comparability between the 2 Caribbean Hispanic data sets and to check SNP calling between the Illumina 650Y and 610K SNP chips, we compared allele frequencies for common randomly selected SNPs.', {'entities': [(104, 136, 'Illumina assay')]}),
 (' Briefly, genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(44, 86, 'Affymetrix assay')]}),
 (' We applied the same quality control criteria as with the Affymetrix 6.0 array data.', {'entities': [(58, 78, 'Affymetrix assay')]}),
 (' ARIC samples were genotyped using the Affymetrix Genome-Wide Human 6.0 array.', {'entities': [(39, 77, 'Affymetrix assay')]}),
 ('Genotyping for the AGS discovery subjects was conducted by deCODE Genetics using Illumina’s HumanCNV370-duo BeadChip as previously described ().', {'entities': [(81, 116, 'Illumina assay')]}),
 ('Totally, 840 KORA controls were genotyped on 550K Illumina arrays and 5667 WTCCC2 controls on the Illumina 1.2M Custom Duo array; cases were genotyped on the Illumina 660K.', {'entities': [(50, 65, 'Illumina assay')]}),
 ('enotype armonization Participants in the eMERGE Network and GENEVA were genotyped using Illumina HumanHap660-Quad chips (Illumina, San Diego, CA) ().', {'entities': [(88, 119, 'Illumina assay')]}),
 (' The samples were clustered by first applying Illumina’s cluster definition, removing samples with call rates less than 0.90, and then re-clustering using the samples themselves.', {'entities': []}),
 (' The HumanHT-12 Expression BeadChips (Illumina Inc, San Diego, CA, USA) contains 48,803 probes that cover more than 25,000 annotated genes.', {'entities': []}),
 ('The platforms used were Affymetrix 500K GeneChip array (four studies), Illumina HumanHap 550 Beadchip (one study), Illumina 317K (four studies), Affymetrix Genome-Wide SNP6.0 (one study), Illumina Hap370cnv (one study), Illumina Hap300 v1 (one study) and Illumina Hap300 v2 (two studies).', {'entities': [(71, 101, 'Illumina assay'), (24, 54, 'Affymetrix assay')]}),
 (' Genotype clusters for each SNP were determined using the Illumina BeadStudio Module (version 3.3.', {'entities': []}),
 (' The North American SSc patient group was genotyped at Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, using the Illumina Human610-Quad BeadChip capturing 89% of the HapMap CEU variation at r_2  > 0.8.', {'entities': [(183, 214, 'Illumina assay')]}),
 (' Data from TCGA on RCC cases were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(54, 96, 'Affymetrix assay')]}),
 ('MESA European Americans, Hispanics, and Chinese were typed on the Affymetrix 6.0 SNP array at Affymetrix Research Services Lab.', {'entities': [(66, 90, 'Affymetrix assay')]}),
 (' We used the Affymetrix® Genome-Wide Human SNP Array 6.0 to obtain genotypes for TGCT cases.', {'entities': [(13, 56, 'Affymetrix assay')]}),
 (' Samples run on Affymetrix 500K Array were called using the BRLMM algorithm, and samples analyzed on Affymetrix Array 5.0 were called using the BRLMM-P algorithm.', {'entities': [(16, 121, 'Affymetrix assay')]}),
 (' Individuals were genotyped on the Illumina Human610 Genotyping Beadchip (, ).', {'entities': [(35, 72, 'Illumina assay')]}),
 (" Discovery genotyping was performed using the Illumina Human CNV370 Quad whole genome genotyping beadchip, following the manufacturer's protocol (Illumina, San Diego, CA, USA) (,).", {'entities': [(46, 105, 'Illumina assay')]}),
 ('Genotyping in AABC was conducted using the Illumina Human1M-Duo BeadChip.', {'entities': [(43, 72, 'Illumina assay')]}),
 ('The TwinsUk sample has been genotyped using the Illumina HumanHap 300k duo chip, and population substructure has been detected and removed as described previously [].', {'entities': [(48, 79, 'Illumina assay')]}),
 (' The first-stage genotyping of this study was performed using the Affymetrix Genome-Wide SNP Array 6.0 (1000K) (Affymetrix, Santa Clara, CA).', {'entities': [(66, 102, 'Affymetrix assay')]}),
 ('Genotyping for stage 3 was conducted using a custom-designed Illumina iSelect array, as part of the replication phase 2 of CGEMS.', {'entities': [(61, 83, 'Illumina assay')]}),
 (' Sequencing was performed using Illumina’s HiSeq 2000 sequencer.', {'entities': []}),
 ('In the Mayo genome-wide association study, genotyping was done with the Illumina HumanHap 370k and 610k BeadChips (Illumina, San Diego, CA, USA), which contain 373397 and 592532 tag SNPs, respectively.', {'entities': [(72, 113, 'Illumina assay')]}),
 (' We also included 65 participants who were genotyped by using the Affymetrix 6.0 array on the Sequenom genotyping platform and found 100% consistency for data generated on these two platforms.', {'entities': [(66, 86, 'Affymetrix assay')]}),
 ('  DNA was genotyped on the Affymetrix 6.0 array as previously reported (, ), and 597,198 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with HapMap 3 reference populations.', {'entities': [(27, 47, 'Affymetrix assay')]}),
 ('Genotyping was performed on the Affymetrix Genome-Wide Human SNP Array 6.0 platform.', {'entities': [(32, 74, 'Affymetrix assay')]}),
 (' For this purpose, we included autosomal SNPs present on the Illumina Human 370-quad chip and in HapMap release 23a for which we downloaded genotype data for 210 unrelated HapMap samples (60 CEU, 45 HCB, 45 JPT and 60 YRI) (www.', {'entities': [(61, 89, 'Illumina assay')]}),
 ('Cases were ascertained through the National Alopecia Areata Registry (NAAR) with approval from institutional review boards and genotyped on the Illumina HumanHap 610 chip.', {'entities': [(144, 170, 'Illumina assay')]}),
 (' Allele cluster definitions for each marker were determined using Illumina BeadStudio Genotyping Module version 3.1.', {'entities': []}),
 ('0001; (d) all SNPs from the Illumina 1M array on 8q24; (e) all SNPs from the 550k array in the HLA region and (f) all SNPs significant in the CGEMS GWAS with P -trend <.', {'entities': [(28, 45, 'Illumina assay')]}),
 (' Genotype calls were obtained after scanning on the Illumina BeadStation 500GX and analysis using the GenomeStudio software.', {'entities': []}),
 (' Additionally, all markers were re-genotyped on >10% of samples typed with the Illumina platform, resulting in an observed mismatch in <0.5% of samples.', {'entities': [(79, 96, 'Illumina assay')]}),
 (' () dataset described 218 glioblastoma expression samples including 132 samples from three previously published datasets as well as 86 new samples assembled into a single, unified dataset using Affymetrix U133A.', {'entities': []}),
 (' We obtained NIMH genotypes from previously generated GWA data on the Affymetrix 500K platform through a formal application process.', {'entities': [(70, 94, 'Affymetrix assay')]}),
 (', of the University of Washington (herein referred to as the Mullins data set) and consisted of 191 males genotyped on the Affymetrix 500K platform.', {'entities': [(123, 147, 'Affymetrix assay')]}),
 (' Genotyping for 2745 patients with T2D and 3148 healthy controls from NHS and HPFS was done at the Broad Center for Genotyping and Analysis using the Affymetrix Genome-Wide Human 6.0 array (Santa Clara, CA, USA) and the Birdseed calling algorithm ().', {'entities': [(150, 188, 'Affymetrix assay')]}),
 ('  Genotyping was completed on the Illumina Human1M and Human1M-Duo Bead Array in accordance with the manufacturer’s protocol.', {'entities': [(34, 77, 'Illumina assay')]}),
 (' The NINDS controls consisted of 943 Caucasian, non-Hispanic individuals that were genotyped with the Illumina HumanCNV370 Beadchip and were negative for neurological disease by self-report.', {'entities': [(102, 131, 'Illumina assay')]}),
 (' We genotyped the DNA samples from the BMC patients in an earlier phase of the study, with the Illumina HumanCNV370-duo bead chip that comprises ~350,000 SNPs common to the 610 array.', {'entities': [(95, 182, 'Illumina assay')]}),
 ('Nine hundred and fourteen individuals were genotyped for 318,127 autosomal and X-chromosomal SNPs with the Illumina Sentrix HumanHap300 BeadChip; genotypes were automatically called using the proprietary BeadStudio software.', {'entities': [(107, 144, 'Illumina assay')]}),
 (' Affymetrix processed more than 99% of the samples.', {'entities': []}),
 (' The current report drew from among all such subjects those who had been previously genotyped by the Center for Inherited Disease Research using the Illumina 610-quad chip (Illumina, San Diego, CA, USA).', {'entities': [(149, 171, 'Illumina assay')]}),
 (' In the Sardinian cohort, 3,329 and 1,412 individuals were genotyped with the Affymetrix 10K and Affymetrix 500K Mapping array set, respectively, with 436 individuals generating an overlapping dataset.', {'entities': [(78, 126, 'Affymetrix assay')]}),
 (' The final hybrid dataset included 2,543,887 SNPs, of which 584,029 were initially genotyped in the GOLDN population using the Affymetrix 6.0 chip ().', {'entities': [(127, 146, 'Affymetrix assay')]}),
 ('We have conducted several GWASs on different disease outcomes [NHS: breast cancer by Illumina 550, and pancreatic cancer by Illumina 550; HPFS: advanced prostate cancer by Illumina 610; both NHS (part of the CGEMS) (–) and HPFS: coronary heart disease by Affymetrix 6.0, type 2 diabetes by Affymetrix 6.', {'entities': []}),
 (' We obtained a genotype concordance rate with the genotypes produced by the Illumina assays of >99.9%.', {'entities': []}),
 ('  Genotyping was done with the Illumina 550K array (Illumina, San Diego, CA, USA) in self-reported Caucasian individuals.', {'entities': [(31, 50, 'Illumina assay')]}),
 (' Mayo VTE genotyping was performed as part of a larger GWAS of VTE using the Illumina 660W Quad array at the Center for Inherited Disease Research at Johns Hopkins University.', {'entities': [(77, 101, 'Illumina assay')]}),
 (' Unrelated cases with a best-estimate diagnosis of bipolar I disorder were genotyped on the Illumina HumanHap550 array.', {'entities': [(92, 118, 'Illumina assay')]}),
 (" Genotype clusters were determined using Illumina's BeadStudio 2.0 software after first eliminating 240 samples (9.", {'entities': []}),
 (' The SNP in SLC30A8  associated with T2D in the French report (rs13266634) is poorly correlated with SNPs on the Affymetrix chip (r _2 <0.01), and extensive recombination events in the region limit the value of data-imputation methods.', {'entities': [(113, 128, 'Affymetrix assay')]}),
 ('A total of 555,352 SNP genotype assays were attempted on the 2,494 DNA samples using the Illumina HumanHap550 chip.', {'entities': [(89, 114, 'Illumina assay')]}),
 (' Flow Chart of the Experimental Process and SNP Selection Criteria    The two GWASs from Hong Kong and Anhui were conducted with the use of the Illumina 610-Quad Human Beadchip array, as previously reported.', {'entities': [(144, 176, 'Illumina assay')]}),
 (' RNA quality was tested using an Agilent 2100 Bioanalyzer, followed by hybridization to Affymetrix U133 Plus 2.0 Gene-Chips.', {'entities': []}),
 ('A genome-wide scan was performed using the Affymetrix Human Mapping 500K array set according to the manufacturer’s protocol (Affymetrix, Inc, CA, USA).', {'entities': [(43, 78, 'Affymetrix assay')]}),
 (' Genotype data for Dutch and German controls was obtained from the Illumina Human 550K BeadChip available from a previous study _, .', {'entities': [(67, 95, 'Illumina assay')]}),
 (' Genotypes were called using the Affymetrix Birdseed v2 algorithm.', {'entities': []}),
 (' Given a polymorphic locus t  in the genome, we indicate with (t ) the frequency of the reference allele in the European population, p ′ the frequency of the reference allele in the Illumina European cohort, with  the frequency of reference allele in the African population, with p ′ the frequency of the reference allele in the Illumina African American cohort, and m=21%  the expected European ancestry in African American samples.', {'entities': []}),
 (' Genotypes for each individual passed Affymetrix quality control metrics with a contrast quality control threshold >0.4 and provided calls for >97% of SNP genotypes.', {'entities': []}),
 ('Framingham participants were genotyped using the Affymetrix (Santa Clara, CA) GeneChip Human Mapping 500K Array Set, which was comprised of two arrays generating approximately 262,000 SNPs with Nsp arrays and 238,000 SNPs with Sty arrays.', {'entities': [(49, 111, 'Affymetrix assay')]}),
 (' As described by , the genotyping platform used was Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetryx Inc.', {'entities': [(52, 94, 'Affymetrix assay')]}),
 (' For SP2, a total of 2867 blood-derived samples were genotyped using Illumina HumanHap 550v3, 610Quad, and 1Mduov3 platforms.', {'entities': [(69, 124, 'Illumina assay')]}),
 (' The UK Stage I samples were genotyped using the Illumina Human Hap550 platform, while the UK and Australian Stage II samples were genotyped using a custom Infinium iSelect.', {'entities': [(49, 79, 'Illumina assay')]}),
 (' Samples were genotyped using the Illumina 550K and 610-Quad platforms (, ).', {'entities': [(34, 70, 'Illumina assay')]}),
 (' Genotyping for the TNBCC GWAS was conducted on 1718 cases from 10 studies (ABCTB, BBCC, DFCI, FCCC, GENICA, MARIE, MCBCS, MCCS, POSH, SBCS) using the Illumina 660-Quad SNP array.', {'entities': [(151, 178, 'Illumina assay')]}),
 (' The analysis of rs872071 involved genotyping information taken from the Illumina 317K array utilized in the GenoMEL GWAS.', {'entities': [(73, 92, 'Illumina assay')]}),
 (" Phase 1 of the UK-GWA study was conducted using Illumina Human550 BeadChips according to the manufacturer's protocols (Illumina, San Diego, USA).", {'entities': [(49, 76, 'Illumina assay')]}),
 (' Cases were recruited soon after confirmed diagnosis of adenocarcinoma of large bowel (phase 1, aged ≤55 years; phase 2, aged <80 years), We genotyped individuals in phase 1 using Illumina HumanHap300 and HumanHap240S arrays on the Infinium platform, and we genotyped individuals in phase 2 using the Illumina iSelect custom panel.', {'entities': [(180, 249, 'Illumina assay')]}),
 (' Genotyping was performed at The Rockefeller University Genomics Resource Center using the Illumina 300K SNP Infinium platform (Sentrix HumanHap 300) according to the manufacturer’s recommended protocol.', {'entities': [(91, 126, 'Illumina assay')]}),
 (' TwinsUK: Framingham Osteoarthritis Study: samples from 9274 individuals were genotyped using the Affymetrix GeneChip® Human Mapping 500K array set and the 50K supplemental array set focused on coding SNPs and SNPs tagging protein-coding genes (Santa Clara, California) as part of the SHARE initiative.', {'entities': [(98, 143, 'Affymetrix assay')]}),
 (' We started with 1,057 cases and 558 examined controls and studied 906,000 genotyped SNPs and 946,000 CNVs using the Affymetrix 6.0 GeneChip, which passed QC filters.', {'entities': []}),
 (' To prioritise SNPs for follow-up amongst lower-ranked loci from the Australian GWAS, we performed a fixed-effects meta-analysis of our results (after excluding the 1,230 overlapping samples from Busselton) with those published and made available by the GABRIEL (), which were based on 10,365 asthmatic patients and 16,110 controls genotyped with the Illumina 610K array.', {'entities': [(351, 370, 'Illumina assay')]}),
 ('All GWA studies were genotyped using the Affymetrix GeneChip 500K array set, and genotypes were called using the BRLMM algorithm.', {'entities': [(41, 71, 'Affymetrix assay')]}),
 (' In the Harvard study, genotyping was done with the Illumina Human610-Quad BeadChip.', {'entities': [(52, 83, 'Illumina assay')]}),
 (' Genotyping was performed with the Affymetrix 5.0 SNP chip, which contains probes for 500,568 SNPs.', {'entities': [(35, 58, 'Affymetrix assay')]}),
 (' To facilitate comparison of the association results with top SNPs from other BMD GWAS typed on different platforms, we used the IMPUTE software () to generate genotype data for the SNPs in HapMap release 27 using the Illumina 610Quad genotypes on our samples and the reference phased haplotypes from HapMap release 27. We limited imputation to only the single chromosomal region in which a SNP associated in a previous study was not included in the Illumina array genotyped in this sample.', {'entities': [(218, 464, 'Illumina assay')]}),
 (' To maximize the ethnic homogeneity of the case patient and control subject series, we performed a principal components analysis using a subseries of 11\u2009029 SNPs present on all Illumina BeadChip panels (Illumina Inc) that are evenly distributed across the genome in low linkage disequilibrium (LD) (r _2  < 0.004) () and that passed quality control requirements.', {'entities': [(177, 194, 'Illumina assay')]}),
 (' Each study participant in GoKinD was genotyped using the Affymetrix SNP Array 5.0.', {'entities': [(58, 82, 'Affymetrix assay')]}),
 (' Genotyping was performed using the 500\u2009K Affymetrix GeneChip and the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix Inc.', {'entities': [(42, 112, 'Affymetrix assay')]}),
 ('We genotyped the 100 RA cases and 600 controls using the Affymetrix Genome-Wide Human SNP array 5.0 platforms (Affymetrix, Santa Clara, CA).', {'entities': [(57, 99, 'Affymetrix assay')]}),
 (' Genotyping was undertaken using Illumina HumanHap 550K SNP chips and full phenotype and raw genotyping data are available at https://queue.', {'entities': [(33, 65, 'Illumina assay')]}),
 (' The Human1M and Human1M-Duo contain 415 and 436 SNPs, respectively, that were genotyped as part of a candidate gene study on the Illumina GoldenGate platform on a subset of the individuals genotyped in this study (N=444).', {'entities': [(130, 158, 'Illumina assay')]}),
 (' Genomic DNA samples from the MGH were genotyped using the Illumina Human1M BeadChip (N=1,057,265 SNPs) while the UCLA samples were genotyped using the Illumina Human 1M-Duo array (N=1,151,846 SNPs).', {'entities': [(59, 84, 'Illumina assay')]}),
 (' Locus-specific imputation was performed to examine 12 additional SNPs not genotyped on the Affymetrix 5.0 platform but that had previously been reported to be associated with DN.', {'entities': [(92, 115, 'Affymetrix assay')]}),
 ('Genotyping in the CGEMS project was carried out using the Illumina Infinium Sentrix HumanHap550 bead chip, which contains 556 566 SNPs derived from the HapMap phase I and II data ().', {'entities': [(58, 105, 'Illumina assay')]}),
 (' Samples from 43 case subjects and 200 control subjects from the EPIGEN consortium were genotyped with the use of the Illumina 610K Quad platform at the Duke University Center for Human Genome Variation.', {'entities': [(118, 145, 'Illumina assay')]}),
 (' Considering the relatively low coverage of Illumina HumanHap300 v1.1 BeadChips, we also compared the results by mapping SNPs within 20kb around the gene and by mapping SNPs within 100kb around the gene.', {'entities': [(44, 79, 'Illumina assay')]}),
 (' Biotinylated cDNA (750 ng) was hybridized to Illumina HumanHT-12 Expression BeadChips according to the manufacturer’s protocol.', {'entities': [(46, 86, 'Illumina assay')]}),
 (' These samples were genotyped in the context of a larger GWAS, which resulted in the genotyping of 16,140 individuals with the use of the Illumina 317, 370, and 610 SNP chips.', {'entities': [(138, 174, 'Illumina assay')]}),
 ('  All subjects from the Family Heart Study were genotyped on the Illumina HumMap 550 chip.', {'entities': [(65, 89, 'Illumina assay')]}),
 (' Genotyping was performed using Illumina HumanHap 550K SNP chips (Illumina Inc.', {'entities': [(32, 64, 'Illumina assay')]}),
 (' The bipolar subjects and controls were genotyped using the Affymetrix 500K array whereas the schizophrenia subjects were genotyped using the Affymetrix Genome Wide Human SNP Array 5.0 and both sets of cases were shown to be genetically well-matched to the control sample (; ).', {'entities': [(60, 184, 'Affymetrix assay')]}),
 (' Additionally, we included 223 cognitively-normal controls with no PD symptoms by self-reported symptom questionnaire () from a previous GWAS () of late-onset Alzheimer disease (LOAD) genotyped using the Illumina HumanHap 550 BeadChip, and another 164 cognitively-normal controls from a second LOAD study with no self-reported PD symptoms by questionnaire () genotyped using the 1M-Duo Infinium HD BeadChip.', {'entities': [(204, 234, 'Illumina assay')]}),
 (' After sample processing, genome-wide genotyping was performed using the Affymetrix Genome Wide Human SNP Array 6.0 ().', {'entities': [(73, 115, 'Affymetrix assay')]}),
 (' Genotyping was performed by the Center for Inherited Disease Research using the Illumina Human1M-Duo BeadChip system.', {'entities': [(81, 110, 'Illumina assay')]}),
 (' The TCGA dataset () has 326 primary glioblastoma expression samples using the Affymetrix U133A expression platform.', {'entities': [(79, 115, 'Affymetrix assay')]}),
 (' Genotyping for all cases was performed with the Illumina® Human610–610K Quad platform at the Duke University Center for Human Genome Variation (NC, USA).', {'entities': [(49, 86, 'Illumina assay')]}),
 ('The beta-globin region was sequenced in 62 randomly selected Gambian control individuals who had previously been genotyped on the Affymetrix 500K array.', {'entities': [(130, 151, 'Affymetrix assay')]}),
 (' Genotyping was performed on the Illumina Human610Quadv1_B BeadChips (Illumina, San Diego, CA) by the Center for Inherited Disease Research using the Illumina Infinium II assay protocol ().', {'entities': [(33, 68, 'Illumina assay')]}),
 (' As described elsewhere, DNA extracted from the baseline WGHS blood samples underwent SNP genotyping using the Illumina Infinium II assay to query a genomewide set of 318,237 SNP markers (Human HAP300 panel) as well as an additional focused panel of 45,751 SNPs selected to enhance coverage of genomic regions without regard to allele frequency in which we had a strong a priori interest owing to presence of genes thought to be of relevance to metabolic, lipid, inflammatory, and other biological functions.', {'entities': []}),
 (' Specifically, among the Maywood individuals genotyped on the Affymetrix 6.0 array, 141 individuals were previously genotyped at 599 SNP loci on chromosome 3q27 not found on the Affymetrix 6.', {'entities': [(62, 82, 'Affymetrix assay')]}),
 (' Autosomal perfect-match SNPs supported by Affymetrix (n  = 868,157) were evaluated for Mendelian inheritance in CEPH trios (389 dropped), SNP call rates of >95% (39,220 dropped), Hardy Weinburg equilibrium (HWE; P  > .', {'entities': []}),
 (' Amongst the Hutterites, rs9469220, rs7751374, rs10124954, rs537526, and rs16977747 were genotyped on the Affymetrix 6.0 GeneChip, and rs613614, rs2101567, rs9314043, and rs11075734 were used as genotype proxies for rs321588, rs2363709, rs13361473, and rs6499255, respectively.', {'entities': []}),
 ("Genotyping was performed at Children's Hospital of Philadelphia (CHOP) using the Illumina Human550 platform (n=70) and the Medical Genetics Institute at CSMC using the Illumina Human610 platform for CD samples (n=17) and HumanCNV370 platform for UC samples (n=11) ().", {'entities': [(81, 107, 'Illumina assay')]}),
 (' () Genotyping for the TCGA study subjects was performed using Illumina 550 platform.', {'entities': [(63, 84, 'Illumina assay')]}),
 ('GWA genotype data were obtained by applying samples to an Affymetrix 6.0 SNP array.', {'entities': [(58, 82, 'Affymetrix assay')]}),
 (' GHS participants were typed with the Affymetrix Genome-Wide Human SNP Array 6.0 as previously described.', {'entities': [(38, 80, 'Affymetrix assay')]}),
 (' Genotyping for the replication samples from Helsinki was conducted using the Illumina 550 platform as previously described ().', {'entities': [(78, 99, 'Illumina assay')]}),
 (' Using a label corresponding to the genotyping center as a covariate gave a similar λ to just using the data that was genotyped at Affymetrix (λ = 1.095, λ = 1.', {'entities': []}),
 ('All subjects were genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA) according to protocols of the London Regional Genomics Centre (www.', {'entities': [(34, 76, 'Affymetrix assay')]}),
 (' Australian twin and endometriosis sample controls were genotyped at deCODE Genetics (Reykjavik, Iceland) on the Illumina HumanHap610W Quad and Illumina HumanHap660 Quad Beadarrays, respectively.', {'entities': [(113, 180, 'Illumina assay')]}),
 (' For the BRASS cases and NIMH controls, GWA data on Affymetrix 6.0 (unpublished data) and Affymetrix 500K platforms were available, respectively.', {'entities': [(52, 115, 'Affymetrix assay')]}),
 (' An additional Affymetrix 50K Array (HuGeneFocused50K) with gene-centric and coding SNPs was also genotyped for a total of approximately 550K SNPs.', {'entities': [(15, 35, 'Affymetrix assay')]}),
 ('0, GeneChip 500K, 250K, MIP50K and 10K) and Illumina (HumanHap 550K, 318K, HumanHap 300K, HumanHap 370K CNV, HumanHap610 quad, Human660W-Quad BeadChip, 6K and Human 1Mv1_C) genotyping arrays.', {'entities': [(44, 150, 'Illumina assay')]}),
 ('Genotypes for 635 PD cases and 255 PD controls were generated using the Illumina Infinium 610-quad BeadChip (Illumina, San Diego, CA, USA) and the Illumina Infinium II assay protocol ().', {'entities': [(72, 107, 'Illumina assay')]}),
 ('The SHARe project () genotyped 9274 FHS participants, using the Affymetrix 500K mapping array and the Affymetrix 50K supplemental array.', {'entities': [(64, 93, 'Affymetrix assay')]}),
 (' Persons for the initial GWAS analysis on VT were typed with the Illumina Sentrix HumanHap300 Beadchip with genotyping quality control criteria previously described.', {'entities': [(65, 102, 'Illumina assay')]}),
 (' GWAS of the iControls population () was performed using Illumina Hap300 and Hap550 chips.', {'entities': [(57, 89, 'Illumina assay')]}),
 ('Genome-wide association scans were performed using the Affymetrix 500K mapping array, the Illumina 317K array and Perlegen Sciences customised arrays.', {'entities': [(90, 109, 'Illumina assay'), (55, 84, 'Affymetrix assay')]}),
 (' Genotyping for Pittsburgh subjects was performed using the Illumina Omni1-Quad chip (containing probes for 1.13 million SNPs).', {'entities': [(60, 84, 'Illumina assay')]}),
 (' This is the consequence of several factors including: less-than-complete coverage of common variation genome-wide on the Affymetrix chip; poor coverage (by design) of rare variants, including many structural variants (thereby reducing power to detect rare, penetrant, alleles); difficulties with defining the full genomic extent of the gene of interest; and, despite the sample size, relatively low power to detect, at levels of significance appropriate for genome-wide analysis, variants with modest effect sizes (odds ratio (OR) < 1.2).', {'entities': [(122, 137, 'Affymetrix assay')]}),
 (' Genotyping was performed using the Illumina Infinium II assay protocol with hybridization to Illumina HumanHap 1M BeadChips (Illumina, San Diego, CA, USA).', {'entities': [(36, 124, 'Illumina assay')]}),
 (' Briefly, the genotyping was performed on the Illumina BeadArray Reader at the Centre for Applied Genomics (Toronto, Ontario, Canada) using 250 nanograms of DNA.', {'entities': [(46, 64, 'Illumina assay')]}),
 (' Genetic data for all stages were obtained via the Affymetrix 6.0 array for 1,264 African American and 1,358 Caucasian HyperGEN and 989 GENOA participants.', {'entities': [(51, 71, 'Affymetrix assay')]}),
 (' Genotyping was performed using the Affymetrix Gene Chip Human Mapping 500K Array Set at the Broad Institute of Harvard and MIT using standard protocols and quality control, and addressing potential population stratification as previously described (, ).', {'entities': [(36, 56, 'Affymetrix assay')]}),
 (' RAFs calculated from the control pools were compared with allele frequencies calculated from the individual genotyping on 166,033 SNPs which overlapped between the Affymetrix 6.0 chip and the Illumina HuHap550-Duo BeadChip.', {'entities': [(193, 223, 'Illumina assay'), (165, 184, 'Affymetrix assay')]}),
 (' RNA from the tissue biopsies was hybridized to Affymetrix ST 1.0 Exon arrays and obtained scans were RMA normalized and log2 transformed.', {'entities': [(48, 77, 'Affymetrix assay')]}),
 (' () dataset contains 75 glioblastoma expression samples using the Affymetrix U133. Normalized expression values using the standard RMA method for the Lee and Murat datasets were downloaded from the NCBI GEO database (GSE13041 and GSE7696).', {'entities': []}),
 (' For three studies (TOR, NCO, MAY) genotype data were available from an independent, ongoing GWAS study that is also used the Illumina Infinium 610K platform.', {'entities': [(126, 157, 'Illumina assay')]}),
 ('Pedigrees members of the GAIT study were typed with the Illumina Infinium 317 Beadchip as previously described.', {'entities': [(56, 86, 'Illumina assay')]}),
 (' Almost all of the variants in the Illumina 550Kv3 chip are also included in the Illumina 1M-Duo chip, so there was not an additional loss of coverage when comparing results for the two platforms.', {'entities': [(35, 195, 'Illumina assay')]}),
 (' After staining, each BeadChip was imaged on the Illumina BeadArray 500GX Reader using Illumina BeadScan image data acquisition software (version 3.2.', {'entities': [(49, 70, 'Illumina assay')]}),
 (' PWV was assessed with the Complior®SP device (Artech Medical, Pantin, France) before the interventions were administered, and genotyping was performed with an Affymetrix 500K chip.', {'entities': [(160, 180, 'Affymetrix assay')]}),
 ('In the four CARe cohorts, individual estimates of the proportion of African relative to European ancestry was calculated from 3192 independent ancestry informative markers included on the Affymetrix 6.0 array using the Markov Chain Monte Carlo algorithm implemented in ANCESTRYMAP as in previous studies.', {'entities': [(188, 208, 'Affymetrix assay')]}),
 (' NIDDK controls consisted of 895 individuals of non-Jewish, European ancestry that were genotyped with the Illumina HumanHap300 Beadchip and were without history of inflammatory bowel disease.', {'entities': [(107, 136, 'Illumina assay')]}),
 ('We used the Illumina Infinium 370 CNV chip to obtain GWA data on the cases (See , Genome-wide association screen: subjects and selection of SNPs).', {'entities': [(12, 42, 'Illumina assay')]}),
 (' Genotyping of GWAS samples was performed at the Center for Inherited Disease Research using 1 μg of genomic DNA on Affymetrix Genome-wide Human SNP array 6.0.', {'entities': [(116, 158, 'Affymetrix assay')]}),
 (' Genotyping information for rs872071 was taken from the Illumina 317K data generated for the GWAS.', {'entities': [(56, 69, 'Illumina assay')]}),
 (', of the Laboratory for Genetic Diversity (LGD) at the National Cancer Institute, and consisted of 1,877 males genotyped on the Affymetrix 6.0 platform.', {'entities': [(128, 151, 'Affymetrix assay')]}),
 (' Genotyping was conducted using the Affymetrix 500K mapping array and the Affymetrix 50K gene-focused macrophage inflammatory protein array.', {'entities': [(36, 65, 'Affymetrix assay')]}),
 (' For one study, Illumina Infinium 317K data were used with imputation based on HapMap CEU data following 100 iterations in MACH version 1.0.', {'entities': []}),
 (' To avoid edge effects in haplotype phasing and imputation, the data for each sequenced sample was extended by including SNPs from the Affymetrix array flanking both ends of the sequenced region, creating a 1-Mb region centered on rs334 (at 5,204,808 in build 35) from 4,705,000 to 5,705,000 spanning 453 SNPs in total.', {'entities': [(135, 151, 'Affymetrix assay')]}),
 (' For the results from the Affymetrix 6.0 platform, genomic control correction was applied to individual-study results with genomic control factor (λ) >1 prior to meta-analysis.', {'entities': [(26, 49, 'Affymetrix assay')]}),
 ('DNA was extracted from blood and genotyped on the Affymetrix 6.0 array, as previously reported_,  .', {'entities': [(50, 70, 'Affymetrix assay')]}),
 (' Genotyping of a genome-wide set of 307\u2009984 SNPs was performed using the Illumina Infinium 317k Beadchip.', {'entities': [(73, 104, 'Illumina assay')]}),
 ('0 Array (Affymetrix, Santa Clara, USA) was conducted to discover SNPs associated with CAD in the CADomics study (Coronary Artery Disease and Genomics), a case-control study of CAD (2,078 CAD cases and 2,953 controls).', {'entities': []}),
 ('Genome-wide genotyping of cHL case patient samples was performed using the Illumina Infinium Human660-Quad BeadChip (Illumina Inc, San Diego, CA) at the Centre National de Génotypage (Evry, France; http://www.', {'entities': [(75, 115, 'Illumina assay')]}),
 ("Samples were genotyped using the Illumina HumanCytoSNP-12™ array utilizing Infinium® HD Assay Ultra genotyping assay methods (∼300,000 single nucleotide polymorphisms (SNPs)) according to the manufacturer's instructions at the genotyping facilities located at OMRF (Oklahoma City, OK).", {'entities': [(33, 64, 'Illumina assay')]}),
 (' Genotyping was performed at the Center for Inherited Disease Research (CIDR) using 1µg of genomic DNA (diluted in 1X TE buffer and at 50ng/µl) on the Affymetrix Genome-wide Human SNP array 6.0 (Affymetrix, Santa Clara, CA, USA).', {'entities': [(151, 193, 'Affymetrix assay')]}),
 (' To avoid SNPs with genotyping errors in the Gambian study, we used only SNPs on the Affymetrix platform for the Gambian data with minor allele frequency >41% and missingness <5% in both case and control cohorts, and with Hardy-Weinberg equilibrium P  ≥ 10_−7  in controls as the input for IMPUTE.', {'entities': [(85, 104, 'Affymetrix assay')]}),
 ('0, kidney stone by Illumina 610 and glaucoma by Illumina 660].', {'entities': []}),
 ('The genotyping for the GWAS - which was part of the German GWAS initiative funded by the National Genome Research Network (NGFN) - was performed by Illumina’s service facility (San Diego, CA, USA) using the Illumina HumanHap 550k v1 with 561,466 SNP markers (San Diego, CA, USA).', {'entities': []}),
 (' Samples were genotyped by the Genetic Resource Core Facility SNP Center at Johns Hopkins University using Illumina GoldenGate chemistry and a custom panel of 768 SNPs (GS0012520-OPA) (see ).', {'entities': []}),
 (' Controls had been genotyped previously using the Affymetrix_®  Genome-Wide Human SNP Array 6.0 platform and had passed the same genotyping quality measures used for TGCT cases.', {'entities': [(50, 95, 'Affymetrix assay')]}),
 ('A set of 374 SNPs on the Illumina 317K SNP chip that had previously been implicated as being associated with autoimmune diseases were identified from published genome-wide association studies; 207 of these passed our statistical quality control standards.', {'entities': [(25, 47, 'Illumina assay')]}),
 ('Genotyping was performed at the Broad Institute and Center for Inherited Disease Research on the Illumina 660W and 1M Bead Chips (Illumina Inc, San Diego, CA, USA).', {'entities': [(97, 128, 'Illumina assay')]}),
 (' All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute Biological Sample Repository (BSP).', {'entities': [(25, 58, 'Illumina assay')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio genotyping module version 3.2.', {'entities': []}),
 ('Genomic DNA from 1,440 AD cases was genotyped using the Illumina HumanOmni1-Quad as part of the stage 1 discovery sample.', {'entities': []}),
 (' Among the individuals examined, 1,412 were genotyped with the Affymetrix Mapping 500K Array Set.', {'entities': [(63, 92, 'Affymetrix assay')]}),
 (' The original genotype data contained 620,903 markers, including 620,901 genomic markers on the Illumina chip plus 2 APOE SNPs whose values were obtained from the APOE status data.', {'entities': [(96, 109, 'Illumina assay')]}),
 (' In the ERF study 1000 individuals were genotyped with Illumina 300k, 100 individuals with Illumina 370k arrays and 200 individulas with the Affymetrix 250k array.', {'entities': [(55, 111, 'Illumina assay'), (141, 162, 'Affymetrix assay')]}),
 ('  The Center for Inherited Disease Research (CIDR), one of two genotyping centers supported by the Gene, Environment Association Studies Consortium (GENEVA) consortium,[] genotyped DNA samples using the Illumina Human660-Quad v.', {'entities': []}),
 (' The 116 cases with cardiac neonatal lupus were compared with 3,351 Caucasian controls genotyped on the Illumina HAP300 SNP chip (~317,000 single-nucleotide polymorphisms [SNPs]) from the Consortium on Systemic Lupus Erythematosus (SLE) Genetics ().', {'entities': [(104, 128, 'Illumina assay')]}),
 (' DNA samples were collected in accordance with standard protocols and submitted to different genotype centers using different single nucleotide polymorphism platforms (Illumina 317K, IlluminaHumanCNV370- Quadv3, and Illumina Human 610-Quad, Illumina Inc.', {'entities': [(168, 181, 'Illumina assay')]}),
 ('21 × 10_−5  as proposed for the Illumina 317K panel of markers (adjusted for SNP non-independence) ().', {'entities': [(32, 45, 'Illumina assay')]}),
 (' The US samples were genotyped on the Illumina Human1M chip.', {'entities': [(38, 59, 'Illumina assay')]}),
 (" In the discovery stage, we conducted the genotyping using Illumina Human 610-Quad Beadchips and the infiniumII assay following manufacturer's instructions.", {'entities': [(59, 92, 'Illumina assay')]}),
 (' Genotyping within EPAS1  was conducted using a customer-designed Illumina GoldenGate assay (384 SNP plex) for all samples from Mag Xiang and some of the samples from Zhaxizong Xiang.', {'entities': []}),
 (' All samples were of self-reported causasian ancestry and genotyped on the Illumina HumanHap 550Y product.', {'entities': []}),
 (' Note: CHOP = Children’s Hospital of Philadelphia; IMAGE = International Multicenter ADHD Genetics Project; PUWMa = Pfizer funded study from the University of California, Los Angeles, Washington University, and the Massachusetts General Hospital; SNP = single-nucleotide polymorphismEach of the studies had been conducted on different platforms (Illumina 550K for CHOP, Perlegen 600K for IMAGE, Affymetrix 500K for IMAGE II, and Illumina 1M Duo for PUWMa).', {'entities': [(346, 359, 'Illumina assay'), (395, 410, 'Affymetrix assay'), (370, 383, 'Perlegen assay')]}),
 (' The whole genome genotyping was conducted using the Illumina Veracode platform and 610-Quad high throughput genotyping chips.', {'entities': [(53, 79, 'Illumina assay')]}),
 (' A total of 459 Caucasian individuals with severe mental disorders and 313 healthy controls were recruited and successfully genotyped on Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix Inc.', {'entities': [(137, 179, 'Affymetrix assay')]}),
 (' We genotyped 318,237 SNPs for each individual, using the Illumina 300 HumanHap SNP Chip.', {'entities': [(58, 88, 'Illumina assay')]}),
 ('AD GWAS dataset consists of 188 AD cases with a clinical diagnosis of AD at baseline visit that were genotyped using the Illumina 610- Quad BeadChip.', {'entities': [(121, 148, 'Illumina assay')]}),
 (' The Center for Inherited Disease Research (CIDR), one of two genotyping centers supported by the Gene, Environment Association Studies Consortium (GENEVA) consortium,[] genotyped DNA samples using the Illumina Human660-Quad v.', {'entities': []}),
 (' Genome-wide genotyping was performed using the Affymetrix Genome-Wide Human 6.0 array.', {'entities': [(48, 86, 'Affymetrix assay')]}),
 (' eQTL analysis was performed with genotypes from circulating blood DNA (Illumina 610w-Quad BeadArrays).', {'entities': [(72, 101, 'Illumina assay')]}),
 ('A total of 1543 ALSPAC children were initially genotyped at 317,504 SNPs on the Illumina HumanHap 317K SNP chip.', {'entities': [(80, 111, 'Illumina assay')]}),
 (' Both rapid progressors (AIDS, by the CDC 1993 definition, within 3 years of seroconversion) and slow progressors (CD4+ cell count >500 cells/mL and no clinical symptoms of AIDS at least 8 years after seroconversion) from the French GRIV cohort were typed using the Illumina HumanHap300 genotyping beadchips [, ], as were rapid progressors and controls in the Amsterdam Cohort Study (ACS.', {'entities': [(266, 307, 'Illumina assay')]}),
 ('For the stage 1 discovery analysis, we successfully genotyped 189 individuals with use of the Affymetrix GeneChip Human Mapping 500K Array Set (http://www.', {'entities': [(94, 138, 'Affymetrix assay')]}),
 ('07) for SNPs from Affymetrix 6.0, and 0.', {'entities': []}),
 ('Our analysis of GWA data from the GoKinD collection included 359,193 SNPs genotyped on the Affymetrix 5.0 500K SNP Array, a platform that offers approximately 76% coverage of common variation across the entire genome.', {'entities': [(91, 120, 'Affymetrix assay')]}),
 (' The RNA was extracted and purified, and aliquots were analyzed on Affymetrix GeneChip® Human Genome U133 Plus 2.0 microarrays following standard procedures.', {'entities': [(67, 126, 'Affymetrix assay')]}),
 ('”    Genotyping was carried out at 2 different centres (The Wellcome Trust Sanger Centre, Cambridge, UK and Laboratory Corporation of America, Burlington, NC) using the Illumina Human550 quad array (Illumina, Inc.', {'entities': [(169, 197, 'Illumina assay')]}),
 (' Genotyping in both efforts was performed using the Affymetrix 6.0 array.', {'entities': [(52, 72, 'Affymetrix assay')]}),
 ('98 and manually checked sample quality by means of B-allele frequency and LogR ratio), genotype cluster definitions for each SNP were determined using the ‘Cluster all SNPs’ option in Illumina BeadStudio Genotype module version 3.2.', {'entities': []}),
 (' In EDIC, the Illumina platform was used for which 550K SNPs were available.', {'entities': [(14, 31, 'Illumina assay')]}),
 (' Mayo PGRN subjects who provided blood samples as a source of DNA (n  = 835) were genotyped using the Illumina 610K array, performed at RIKEN, with 830 cases passing genotype quality control.', {'entities': [(102, 121, 'Illumina assay')]}),
 (' Stage 2 was genotyped using a custom-designed iSelect assay from Illumina with content described above; 9,804 samples were attempted (including known duplicates).', {'entities': []}),
 ('Among the 500,568 SNPs present in Affymetrix Whole Genome Human SNP Array 5.0, 440,734 SNPs were accessible after excluding hidden SNPs.', {'entities': [(34, 77, 'Affymetrix assay')]}),
 (' DILGOM and GenMets were genotyped with the Illumina HumanHap 610k array.', {'entities': [(44, 72, 'Illumina assay')]}),
 (' Concordance between genotype calls obtained from the Affymetrix® chip and TaqMan assays for these four makers was 100%.', {'entities': [(54, 70, 'Affymetrix assay')]}),
 (' The RNA was then reverse transcribed and biotin labeled for hybridization with Affymetrix U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA).', {'entities': []}),
 (' Genotyping was performed with the Affymetrix 10K and 500K Mapping Arrays in 3,329 and 1,412 individuals respectively (436 subjects were genotyped with both chips).', {'entities': [(35, 162, 'Affymetrix assay')]}),
 ('[, ] CAMP probands were genotyped on Illumina’s Human-Hap550 Genotyping BeadChip (Illumina, Inc.', {'entities': [(37, 80, 'Illumina assay')]}),
 ('Genomewide analysis of samples that were initially available from the 22 Liverpool subjects with carbamazepine-induced hypersensitivity syndrome was performed with the use of the Illumina Infinium 1.2M chip at the Wellcome Trust Sanger Institute.', {'entities': [(179, 206, 'Illumina assay')]}),
 (' Briefly, the initial 300 subjects were genotyped using the Affymetrix GeneChip Mapping 500K Array Set, and the remaining 3918 subjects were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(60, 203, 'Affymetrix assay')]}),
 ('Genotypes for stage 1 cases were generated using a custom Illumina Infinium 670k array and controls were genotyped using an Illumina Infinium 1.2M array at the Wellcome Trust Sanger Institute.', {'entities': [(58, 86, 'Illumina assay')]}),
 (' To validate the genotyping accuracy in stages 1 and 2, we genotyped the 216 SNPs in 104 (52 case and 52 control) samples using both an Affymetrix 500K Array Set and the iSelect system and analyzed the genotype concordance between the 2 systems (see SI Text ).', {'entities': [(136, 157, 'Affymetrix assay')]}),
 (' Genotyping for the Mayo Clinic study subjects was performed using Illumina 610Quad SNP arrays as previously described ().', {'entities': [(67, 94, 'Illumina assay')]}),
 (' Genotyping was carried out at 2 different centres (The Wellcome Trust Sanger Centre, Cambridge, UK and Laboratory Corporation of America, Burlington, NC) using the Illumina Human550 quad array (Illumina, Inc.', {'entities': [(165, 193, 'Illumina assay')]}),
 ('), 43% male) using the Illumina CytoSNP12 array, and imputation of missing HapMap2 genotypes was done using Beagle 3.1.', {'entities': [(23, 47, 'Illumina assay')]}),
 (' The DNA was screened for ∼909,000 SNPs using Affymetrix6.0 arrays (Affymetrix, Santa Clara, CA).', {'entities': [(46, 66, 'Affymetrix assay')]}),
 ('1 based on the SNP and CNV probes present in the Illumina 610K arrays.', {'entities': [(49, 69, 'Illumina assay')]}),
 (' For the other four GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(82, 102, 'Affymetrix assay')]}),
 (' The discovery sample was genotyped on the Illumina Human 1M\n(for SAGE and COGA) and the replication sample was genotyped on Illumina Human\nCNV370v1 with the same genotype clustering algorithms.', {'entities': []}),
 (' SNP genotypes were called using the Affymetrix BRLMM algorithm []; the mean call rate for all SNPs was 98.5%.', {'entities': []}),
 ('The Australian GWAS included data from 7,197 individuals of whom 5,523 (77%) were genotyped with Illumina 610K (Illumina, San Diego, CA, USA) array 1,674 (23%) with Illumina 370K array as part of four genotyping projects that are summarised in the  (pp 11): the AAGC (n=1,810), QIMR_610K (n=2,483), QIMR_370K (n=1,674) and Busselton (n=1,230) projects.', {'entities': [(97, 147, 'Illumina assay')]}),
 (' Samples (399) were genotyped using the Illumina HapMap550K.', {'entities': []}),
 (' One of the signals for which we failed to obtain evidence of replication (APOE  in CAD) is poorly tagged by the Affymetrix 500K chip.', {'entities': [(113, 133, 'Affymetrix assay')]}),
 (' Taking advantage of the relatedness among individuals in the SardiNIA sample, we conducted a second round of computational analysis to impute genotypes for analysis in an additional 2,893 individuals who were genotyped only with the Affymetrix Mapping 10K Array.', {'entities': [(234, 262, 'Affymetrix assay')]}),
 (' The 1,145 women were genotyped using the the Illumina HumanHap500 array as the first stage of a 3 stage GWAS of breast cancer susceptibility.', {'entities': [(46, 72, 'Illumina assay')]}),
 (' All the individuals were genotyped using Affymetrix GeneChip 500K arrays.', {'entities': [(42, 73, 'Affymetrix assay')]}),
 ('We imputed two SNPs, rs16890979 on chromosome 4 and rs1165205 on chromosome 6, which were not on the Illumina Infinium II HumanHap550 SNP chip.', {'entities': [(101, 142, 'Illumina assay')]}),
 ('Genome-wide SNP genotyping was performed in the CAMP sample by Illumina, Inc, on the HumanHap550v3 BeadChip.', {'entities': [(63, 107, 'Illumina assay')]}),
 ('Significant SNPs from the joint CKGen and CARe meta-analysis were replicated in the DCCT/EDIC Study, which currently consists of 1304 Caucasian participants who underwent genotyping on the Illumina 1M SNP chip.', {'entities': [(189, 209, 'Illumina assay')]}),
 (' The stained arrays were scanned with an Affymetrix GeneChip_®  3000 7G scanner at 0.7 μm solution.', {'entities': []}),
 (" Briefly, SNP genotyping was performed using the Affymetrix Genomewide Human SNP Array 5.0, according to the manufacturer's standard protocol.", {'entities': [(49, 90, 'Affymetrix assay')]}),
 (' Samples were genotyped with the Illumina Infinium II HumanHap300 BeadChip and with an Illumina GoldenGate Custom Panel designed to improve genomic coverage around T2D candidate genes.', {'entities': [(33, 74, 'Illumina assay')]}),
 ("The SFBCS () and the NC-BCFR () study samples were genotyped with the Affymetrix 6.0 array according to the manufacturer's instructions (https://www.", {'entities': [(70, 90, 'Affymetrix assay')]}),
 (' The Illumina Infinium cluster plots for the two surrogate SNPs in the novel region in 18q12.3 (rs10775480 and rs10853535) are shown in Supplementary Material, Figure S4.', {'entities': []}),
 (' The GAIN participants were analyzed by using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(50, 92, 'Affymetrix assay')]}),
 (' BeadChips were imaged on the Illumina BeadStation 500 GX at the Center for Human Genomics at Wake Forest University.', {'entities': []}),
 ('All genome-wide SNP genotyping for the discovery cohorts was performed using the Illumina HumanHap550 BeadChip at the Center for Applied Genomics at the Children’s Hospital of Philadelphia.', {'entities': [(81, 110, 'Illumina assay')]}),
 (' Controls were genotyped with the Illumina 370Duo platform.', {'entities': [(34, 58, 'Illumina assay')]}),
 ('Genotyping was performed at the Center for Genotyping and Analysis at the Broad Institute, using the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561,490 SNPs and 95,876 intensity-only probes.', {'entities': [(101, 148, 'Illumina assay')]}),
 (' Genotyping was carried-out as a part of the  project using the Affymetrix 500K mapping array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K supplemental gene focused array on 9,274 individuals.', {'entities': [(64, 93, 'Affymetrix assay')]}),
 (' The genotype data derive from Illumina Human HAP300 genotyping among 670 PRINCE participants, of whom 168 (25.1%) were female.', {'entities': []}),
 (' All subjects from the Family Heart Study were genotyped on the Illumina HumMap 550 chip.', {'entities': [(64, 88, 'Illumina assay')]}),
 (' Participants in the pancreatic cancer study were genotyped with Illumina HumanHap550 and the Human 610-Quad chips.', {'entities': [(65, 114, 'Illumina assay')]}),
 (' We added Myocardial Infarction Genetics Consortium (MIGen) shared controls (), which were genotyped on the same Affymetrix 6.0 GeneChip product, and conducted population stratification analyses using multidimensional scaling in PLINK ().', {'entities': []}),
 (' We also compared the Illumina-based SNP data for each individual participant for a panel of 44 common SNPs that have previously been ascertained in this population using alternative genotyping technologies; this step is used as a secondary check to ensure accurate specimen labeling prior to any analyses.', {'entities': []}),
 ('  Seven hundred and seventy-five African-Americans from Maywood, IL, were genotyped with Affymetrix Genome-wide human SNP array 6.0, which provided genotype data at 909 622 SNPs in the human genome.', {'entities': [(89, 131, 'Affymetrix assay')]}),
 ('Patients were genotyped using the Illumina Human610-quad BeadChip (Illumina, San Diego, CA, USA).', {'entities': [(34, 65, 'Illumina assay')]}),
 (' Cluster plots for this SNP seem good, but it is surrounded by recombination hotspots and has no other SNPs on the Affymetrix chip with r _2 >0.1 ().', {'entities': [(115, 130, 'Affymetrix assay')]}),
 ('Genotyping was conducted through the FHS SHARe (SNP Health Association Resource) project initiated in 2007 on all Framingham Study participants with DNA available using the Affymetrix 500K (250K Sty and 250K Nsp) mapping array with addition of the Affymetrix 50K MIP (gene-centric) supplemental array (Santa Clara, CA, USA).', {'entities': [(173, 226, 'Affymetrix assay')]}),
 ('4) were genotyped for 934,968 SNPs using Affymetrix Power Tools (apt-probeset-genotype 1.10.', {'entities': []}),
 (' In the cases, out of the 1,199,187 variants analyzed by the Illumina 1M-Duo chip, 47 variants were discarded because they showed discordant clustering among different Illumina chips (private communication, Illumina Technical Support, August 11, 2009), 56,590 variants were excluded because more than 10% of genotypes were missing in African Americans and 58,524 were excluded for similar reasons in European Americans.', {'entities': [(61, 81, 'Illumina assay')]}),
 (' DNA also was genotyped by the Illumina GoldenGate platform for 7 single-nucleotide polymorphisms (SNP; SNP Center, Johns Hopkins University).', {'entities': [(31, 59, 'Illumina assay')]}),
 (' Genome-wide assays of SNPs were conducted independently in each cohort using various technologies: Affymetrix 6.0 for ARIC, Illumina 370CNV for CHS, Affymetrix 500K and 50K for FHS, and Illumina 550K v3 for RS.', {'entities': [(187, 200, 'Illumina assay'), (150, 165, 'Affymetrix assay')]}),
 ('Genotyping in the CARe Consortium was conducted using two chips: the IBC SNP chip () in 7112 AA and 22 539 EA participants, and the Affymetrix 6.0 array in 6089 AA participants.', {'entities': [(132, 152, 'Affymetrix assay')]}),
 (' A total of 906,600 SNPs were genotyped using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm [].', {'entities': [(50, 88, 'Affymetrix assay')]}),
 (' Genotyping of both cases and controls was performed using Illumina Infinium HumanHap660W arrays ().', {'entities': [(59, 96, 'Illumina assay')]}),
 ('Affymetrix Power Tools (APT), version 1.10.', {'entities': []}),
 (' Genotyping was performed using the Illumina 370CNV BeadChip system on 3,980 Cardiovascular Health Study (CHS) participants who were free of cardiovascular disease at baseline.', {'entities': [(36, 60, 'Illumina assay')]}),
 ('Genotypes were called using the proprietary software supplied by Illumina (BeadStudio, version 3.2), with imported cluster centres based on HapMap samples (supplied by Illumina) and call threshold set at 0.', {'entities': []}),
 (' AMFS controls were genotyped by Illumina (San Diego) on Illumina Omni1-Quad arrays.', {'entities': [(33, 83, 'Illumina assay')]}),
 (' For gene expression profiling by Affymetrix U95Av2 microarrays, the expression measures for each probe set was extracted and normalized using robust multi-array average protocols from raw CEL files.', {'entities': [(34, 63, 'Affymetrix assay')]}),
 (' Stage 1 included data on 1894 controls and 1854 cases genotyped for 541,129 SNPs using an Illumina Infinium 550k array.', {'entities': [(91, 119, 'Illumina assay')]}),
 (' DNA was genotyped with the Illumina Human610-Quad BeadChip, and 514,073 SNPs passed quality control filters (SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with 34 European reference populations.', {'entities': [(28, 59, 'Illumina assay')]}),
 (' The non-European cases and controls from the MEC were genotyped on the Illumina 610 platform.', {'entities': [(72, 93, 'Illumina assay')]}),
 (' The CGEMS project included 1,145 post-menopausal breast cancer cases from the NHS whose DNA samples were scanned using the Illumina HumanHap500 array (, ).', {'entities': [(124, 150, 'Illumina assay')]}),
 (' The genotyped SNPs in common between the remaining Illumina (N=269,840) and Affymetrix (N=646,601) SNPs were relatively few (N=137,768).', {'entities': []}),
 (' Briefly, samples were genotyped on the Illumina HumanHap 550 (Norway and ECLIPSE) and Quad 610 (NETT) genotyping arrays (Illumina, Inc, San Diego, CA).', {'entities': [(40, 120, 'Illumina assay')]}),
 ('  The original genotype data contained 620,903 markers, including 620,901 genomic markers on the Illumina chip plus 2 APOE SNPs whose values were obtained from the APOE status data.', {'entities': [(97, 110, 'Illumina assay')]}),
 (' Normalized bead intensity data obtained for each sample was loaded into the Illumina Beadstudio 2.0 software which converted fluorescent intensities into SNP genotypes.', {'entities': []}),
 (' To facilitate confirmation of strand and direction between the Illumina and KASPar genotyping assays, we also genotyped 27 SNPs in 10 replicate individuals from the Irish genome scan using the KASPar platform.', {'entities': [(64, 209, 'Illumina assay')]}),
 (' All EUROSPAN cohorts were genotyped using Illumina 317K platform.', {'entities': [(43, 65, 'Illumina assay')]}),
 (' In addition, we genotyped the rest of the CM cases identified in both cohorts who were not in these previous GWASs by Illumina 610. Finally, we included 494 CM cases and 5628 controls.', {'entities': []}),
 (' Samples were processed according to the Illumina Infinium 2 assay manual.', {'entities': []}),
 (' We approximated the ancestral frequencies of the two populations using the Illumina controls cohort in the following way: \n pE(t)∼p′E(t)pA(t)∼p′B(t)−mp′E(t)1−m  This method of estimating the two allele frequencies is conceptually much simpler than the one described in [], which uses a Markov chain Monte Carlo approach to estimate the frequencies both from cases and controls.', {'entities': []}),
 ("Twenty seven SNPs in a 400 kb region surrounding rs1337512 were genotyped on an Illumina BeadStation 500GX instrument using the Infinum II genotyping assays following manufacturer's recommendations.", {'entities': []}),
 (' Each pool was genotyped in duplicate on the Illumina HumanHap550-Duo BeadChip (Illumina, San Diego, CA) using the Illumina Infinium II Assay (http://www.', {'entities': [(45, 78, 'Illumina assay')]}),
 (' The Illumina Human610-Quad Beadchip was used to obtain genotypes for all cases, resulting in 599 011 successfully genotyped SNPs.', {'entities': [(5, 36, 'Illumina assay')]}),
 ('For the initial phase, genotyping was done at the Affymetrix Service Center using the Genome-Wide Human SNP Array 6.0.', {'entities': [(50, 117, 'Affymetrix assay')]}),
 ('_–  The sixth stratum (BWH/TT) is based on data from our previous study enriched with additional 1453 MS cases and 2176 controls, with all samples genotyped on the Affymetrix GeneChip 6.0 platform.', {'entities': [(164, 196, 'Affymetrix assay')]}),
 ('The discovery sample consisted of 1221 healthy donors from the UK Blood Services Common Control (UKBS-CC1) genotyped with the Affymetrix (Santa Clara, CA) 500K Array.', {'entities': [(126, 165, 'Affymetrix assay')]}),
 (" We performed genotyping in BC_NHS using the Illumina HumanHap550 array, as part of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) Project ().", {'entities': [(45, 71, 'Illumina assay')]}),
 ('  The melanoma analysis of rs872071 was conducted within the GenoMEL GWAS data set; rs872071 is on the Illumina 317K array.', {'entities': [(103, 122, 'Illumina assay')]}),
 ('2 % women) which were previously genotyped using the Illumina HumanHap300 BeadChip.', {'entities': [(53, 82, 'Illumina assay')]}),
 ('Genotyping was performed in all stage 1 study participants using the Affymetrix GeneChip Human Mapping 500K Array Set (Affymetrix, Santa Clara, California), including 500 568 single-nucleotide polymorphisms (SNPs).', {'entities': [(69, 113, 'Affymetrix assay')]}),
 ('Genotyping for the discovery set was performed using the Illumina HumanHap610 chip.', {'entities': [(57, 82, 'Illumina assay')]}),
 (' Genotyping was performed using the 500K Affymetrix GeneChip and the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc.', {'entities': [(41, 111, 'Affymetrix assay')]}),
 ('We carried out high-throughput genome-wide SNP genotyping using Illumina Infinium II HumanHap550 BeadChip technology at the Center for Applied Genomics at CHOP, as previously described.', {'entities': [(64, 105, 'Illumina assay')]}),
 ('GWAS genotyping was performed by Affymetrix (Santa Clara, CA) using a Human SNP Array 6.0.', {'entities': [(33, 89, 'Affymetrix assay')]}),
 (' The Illumina 610Q contains the great majority of the HumanHap 550 set of SNP markers plus additional copy number variants.', {'entities': []}),
 (" We first genotyped the whole-genome SNPs of 425 case and 301 control samples on an Affymetrix GeneChip Mapping 500K Array Set, following the manufacturer's instructions.", {'entities': [(84, 122, 'Affymetrix assay')]}),
 (' Overall, 346,831 tagging SNP were genotyped using Illumina Human CNV370-Duo BeadChips (Illumina, San Diego, CA, USA) according to the manufacturer’s protocols, as described previously.', {'entities': [(51, 86, 'Illumina assay')]}),
 (' Genotyping used Illumina Human370 Bead Chips and the Illumina Infinium II assay protocol.', {'entities': [(17, 45, 'Illumina assay')]}),
 ("Genome-wide SNP genotyping was performed using the Affymetrix Human SNP Array 5.0 following the manufacture's protocol.", {'entities': [(51, 81, 'Affymetrix assay')]}),
 ('We selected controls from 3,293 iControls from Illumina iControlDB who had available Illumina 550K array genotype data and who self-reported as Caucasian.', {'entities': [(47, 104, 'Illumina assay')]}),
 (' Data on the NHS were taken from their GWAS, conducted using an Illumina Infinium 550k array (these data were included in stage 4 since they were not used in the analysis of stage 3 and the selection of the three SNPs for stage 4).', {'entities': [(64, 92, 'Illumina assay')]}),
 (' Genotypes were assigned with Illumina Beadstudio 3.0 software (Illumina, Inc.', {'entities': []}),
 (' Standard QC filters were applied and any SNP was removed unless it satisfied all of the following conditions: mean Illumina Beadstudio GenCall scores ≥ 0.7, SNP call rate > 0.', {'entities': []}),
 (" Genotype data from 640 previously QC'd controls, all free of inflammatory diseases, was combined with common controls from the same Epidemiological Investigation of Rheumatoid Arthritis genotyped on the Illumina Hap550 (N=460) and Quad-610 (N=378) BeadChips (total of 1,478 controls).", {'entities': [(204, 258, 'Illumina assay')]}),
 ('  Genotyping was conducted on 9,274 Framingham Heart Study participants using the Affymetrix 500K mapping array and the Affymetrix 50K gene-focused molecular imprinted polymer array (SNP Health Association Resource at http://www.', {'entities': [(82, 111, 'Affymetrix assay')]}),
 ('As previously described in more detail (), DNA samples were genotyped using the Affymetrix 6.0 array at the Broad Institute.', {'entities': [(80, 100, 'Affymetrix assay')]}),
 (' Imputation of SNPs in the 1000 Genomes dataset not represented on the Affymetrix SNP 6.0 array was performed on each ancestral group independently using MACH1.', {'entities': [(71, 95, 'Affymetrix assay')]}),
 (' We genotyped the remaining 979 samples using the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(50, 92, 'Affymetrix assay')]}),
 (' Genotyping was performed using GeneChip 500K arrays at the Affymetrix Services Lab (California): arrays not passing the 93% call rate threshold at P =0.33 with the Dynamic Model algorithm were repeated.', {'entities': [(60, 104, 'Affymetrix assay')]}),
 (' Genotyping was accomplished by use of the Illumina HumanCNV370-quad beadchip (Illumina, San Diego, CA, USA) housing 373,397 markers genotyped with the Infinium Assay.', {'entities': [(43, 77, 'Illumina assay')]}),
 (" Illumina's BeadStudio3.1.", {'entities': []}),
 (' Genotyping was performed using the Illumina Infinium II Human 1M Beadchip.', {'entities': [(36, 74, 'Illumina assay')]}),
 (' The genotyping concordance rate between the Illumina and KASPar assays was 99.3%, with the non-concordant calls being accounted for by two failed assays on the KASPar platform.', {'entities': [(45, 176, 'Illumina assay')]}),
 ('Genotypes for DNA samples extracted from blood were determined at the RIKEN Center for Genomic Medicine in Yokahama, Japan, with Illumina Human610-Quad BeadChips.', {'entities': [(129, 161, 'Illumina assay')]}),
 ('0 × 10_−9 , position mismatches across databases (Illumina, dbSNP and/or HapMap) and call rate <97%.', {'entities': []}),
 (' Standard Illumina protocols were followed, requiring SNP clustering scores greater than 0.4.', {'entities': []}),
 (' Ninety-seven genes could be reliably assigned a probe on the Affymetrix HG_U133AAofAv2 array (); these transcripts were, on average, expressed at higher levels in late erythroblasts (or the precursors of red blood cells, EB3–EB5) compared to other transcripts in the same cell type (P  <0.01 after Bonferroni correction; ).', {'entities': [(62, 93, 'Affymetrix assay')]}),
 (' (Durham, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix Inc.', {'entities': [(25, 67, 'Affymetrix assay')]}),
 (' The melanoma analysis of rs872071 was conducted within the GenoMEL GWAS data set; rs872071 is on the Illumina 317K array.', {'entities': [(102, 121, 'Illumina assay')]}),
 ('We genotyped the DNA samples of the CSSCD and Duke subjects with the Illumina Human610-Quad SNP array that includes more than 600,000 SNPs and covers ~60% of the genome of the HapMap Yoruban (r _2  > 0.8) and 18,000 known genes.', {'entities': [(69, 101, 'Illumina assay')]}),
 (' Fluorescence intensities were quantitated using an Affymetrix array scanner 30007G.', {'entities': [(52, 68, 'Affymetrix assay')]}),
 (" Genotypes were obtained using the Illumina HumanCNV370v1_C array from 750 ng of genomic DNA following manufacturer's protocols (Illumina, Inc.", {'entities': [(35, 65, 'Illumina assay')]}),
 (' Genotyping analyses for the bladder cancer () and renal cancer studies were performed using Illumina’s HumanHap610 chip and HumanHap660 chip, respectively.', {'entities': [(93, 120, 'Illumina assay')]}),
 ('DNA was extracted from lymphoblast cell lines[] and run on the Affymetrix genome-wide human SNP array 6.0 genotyping platform.', {'entities': [(63, 105, 'Affymetrix assay')]}),
 (' Control DNA samples from the pooled GWAS were also genotyped individually on the Affymetrix 6.0 (Affymetrix, Santa Clara, CA) chip as part of another GWAS performed by the Center for Inherited Disease Research (CIDR).', {'entities': [(82, 131, 'Affymetrix assay')]}),
 ('Cases were genotyped using the Affymetrix 5.0 array at the State University of New York Upstate Medical University, Syracuse using the standard protocol issued by Affymetrix.', {'entities': [(31, 51, 'Affymetrix assay')]}),
 (' The data were processed for genotype calling using the Affymetrix® Power Tools (APT) software using the birdseed calling algorithm version 2.0 Affymetrix®, Inc Santa Clara, CA ().', {'entities': []}),
 (' The quality of imputations was checked by comparing imputed and actual genotypes at 78,844 SNPs not present on the Illumina 550K array for 437 individuals for whom these SNPs were directly typed using the Affymetrix 500K chip.', {'entities': [(116, 135, 'Illumina assay'), (206, 226, 'Affymetrix assay')]}),
 ('Genotyping for stage 1 cases was conducted using the Illumina Infinium 610K array at Illumina Corporation.', {'entities': [(53, 81, 'Illumina assay')]}),
 ("Samples were genotyped at Affymetrix's service laboratory on the Genome-Wide Human SNP Array 6.0.", {'entities': [(26, 96, 'Affymetrix assay')]}),
 (' All subjects were genotyped using the Illumina HumanHap550 BeadChip with over 550,000 single nucleotide polymorphism (SNP) markers.', {'entities': [(39, 68, 'Illumina assay')]}),
 (' In the 274 samples that were genotyped with both the Taqman and Illumina assays, there was 100% agreement at the genotype level.', {'entities': []}),
 ('5 µg of genomic DNA (15 ul of 100 ng/ul stock) using Illumina Infinium II HumanHap 300 BeadChips at Cedars-Sinai Medical Center using the Illumina Infinium II assay protocol ().', {'entities': [(53, 96, 'Illumina assay')]}),
 (' Genotyping was performed at the Broad Institute using the Affymetrix SNP 6.0 GeneChip and the Sequenom MassARRAY system for iPLEX assays ().', {'entities': [(59, 113, 'Affymetrix assay')]}),
 (' Controls from the 58BC had been previously genotyped using the Illumina Infinium HumanHap550v1 BeadChip (58BC controls) () and the Illumina Infinium HumanHap550v3 BeadChip (T1DGC controls) ().', {'entities': [(64, 104, 'Illumina assay')]}),
 ('Genotyping for the lung study controls was completed using Illumina’s HumanHap300 v1.1 BeadChips with 317K tagging SNPs ().', {'entities': [(59, 96, 'Illumina assay')]}),
 ('005 in the SBCS GWA scan data for SNPs on Affymetrix 6.0 array (,).', {'entities': [(42, 62, 'Affymetrix assay')]}),
 (' We used the Affymetrix_®  Genome-Wide Human SNP Array 6.0 to obtain genotypes for TGCT cases.', {'entities': [(13, 58, 'Affymetrix assay')]}),
 (' In the Framingham cohort, the SNP Health Association Resource (SHARe) project genotyped 9274 Caucasian participants with the Affymetrix 500K mapping array and the Affymetrix 50K supplemental array (Affymetrix, Santa Clara, CA, USA).', {'entities': [(126, 155, 'Affymetrix assay')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module (Version 2.3.', {'entities': []}),
 ('_, Samples were genotyped using the Illumina Sentrix Human CNV370-Quad BeadChip (Illumina, Essex, UK) containing 338,897 SNP and covering the whole human genome including high density SNP regions within 10 Kb of a referenced sequenced gene, highly conserved regions, regions of copy number variation, major histocompatibility complex regions, mega-satellite and SNP deserts.', {'entities': [(36, 79, 'Illumina assay')]}),
 (' Individuals were genotyped using the Affymetrix 6.0 GeneChip array.', {'entities': [(38, 67, 'Affymetrix assay')]}),
 (' Anderson historical controls were genotyped on the Illumina HumanHap300 BeadChip.', {'entities': [(52, 81, 'Illumina assay')]}),
 (' The association between SNPs in ARID5B  and leukemia-cell gene expression was analyzed by multiple linear regression for each of the 22,283 probe sets on the Affymetrix HG-U133A 2.0 Array (Affymetrix Inc, Santa Clara, CA, USA).', {'entities': [(159, 188, 'Affymetrix assay')]}),
 (' As part of this public-private partnership, DNA from 1,879 available participants of GoKinD were submitted for genotyping on the Affymetrix 5.0 500K SNP Array by the GAIN genotyping laboratory at the Eli and Edythe L.', {'entities': [(130, 159, 'Affymetrix assay')]}),
 ('Genotyping for the discovery set was performed using the Illumina HumanHap300 BeadChip.', {'entities': [(57, 86, 'Illumina assay')]}),
 ('30 in both the CGEMS Illumina and SHARe Affymetrix data were used for a meta-analysis () to examine the association between ∼2.5million polymorphisms and the plasma metabolites.', {'entities': []}),
 (' Control genotypes for 5069 individuals (from the 1958 British Birth Cohort and UK Blood Service) were determined using a custom Illumina 1.2M Beadchip (www.', {'entities': [(129, 151, 'Illumina assay')]}),
 (' This cohort was genotyped using the Illumina HumanHap 300K platform.', {'entities': [(37, 68, 'Illumina assay')]}),
 (' Subsequent genotyping of cases was conducted at CNG in Paris using the Illumina Humancnv370k array.', {'entities': [(72, 99, 'Illumina assay')]}),
 ('0 chip and the Illumina HuHap550-Duo BeadChip.', {'entities': [(15, 45, 'Illumina assay')]}),
 ("Genotyping of cases were conducted using Illumina Infinium HD Human610-Quad BeadChips according to the manufacturer's protocols (Illumina, San Diego, CA, USA; Supplementary Material S1).", {'entities': [(41, 85, 'Illumina assay')]}),
 (' The DNA samples were collected in accordance with standard protocols and were genotyped using the following Illumina SNP platforms: 317K, HumanCNV370-Quadv3, and Human610-Quad.', {'entities': [(109, 131, 'Illumina assay')]}),
 (' In brief, genome-wide SNPs were measured using Affymetrix SNP array 6.0 in an initial set of 8861 participants of European ancestry.', {'entities': [(48, 72, 'Affymetrix assay')]}),
 (' Genotypes were called using BRLMM algorithm (Affymetrix, Inc) for 500K and Birdseed Algorithm for Genome-Wide Human SNP Array 6.0.', {'entities': [(46, 130, 'Affymetrix assay')]}),
 (' Genome-wide genotyping was performed on 830 DNA samples using the Affymetrix 6.0 GeneChip ® Human Mapping 1 million array set (Affymetrix®, Inc Santa Clara, CA).', {'entities': [(67, 122, 'Affymetrix assay')]}),
 (' EA DNAs were genotyped on the Illumina Hum550k Beadarray.', {'entities': [(31, 57, 'Illumina assay')]}),
 ('1% Tween 20), in turn, on an Affymetrix Fluidics Station FS450. Then they were stained subsequently with the Streptavidin Phycoerythrin (SAPE, 10 μg/ml) and Anti-streptavidin antibody.', {'entities': []}),
 ('DNA samples were genotyped using the Illumina HumanOmniExpress BeadChip, consisting of 729 755 SNPs, at the Center for Cancer Genomics, Wake Forest University.', {'entities': [(37, 71, 'Illumina assay')]}),
 ('We genotyped 1815 Latinos recruited in LALES using Illumina OmniExpress BeadChip Kit (730,525 markers; Illumina, Inc.', {'entities': [(51, 80, 'Illumina assay')]}),
 (' These were genotyped in two phases, phase 1 on the Illumina HumanHap300 BeadChip version 2 duo array (317K SNPs) and phase 2 on the Illumina Human610 quad array (610K SNPs).', {'entities': [(52, 81, 'Illumina assay')]}),
 (' Genotyping was performed using the Affymetrix 500K Array Set.', {'entities': [(36, 57, 'Affymetrix assay')]}),
 (' Genotypes for the Illumina arrays were called using the genotyping module made available in the Illumina GenomeStudio 2009.2 software that incorporates the GenTrain 2.', {'entities': [(19, 34, 'Illumina assay')]}),
 ('5 μg of genomic DNA (15 μl of 100 ng/μl stock) and Illumina Infinium II HumanHap 300 BeadChips and assay protocol [].', {'entities': [(51, 94, 'Illumina assay')]}),
 ('), NHSI/NHSII and part of the PLCO study were genotyped previously using the Illumina Human 550 SNP array (Illumina, Inc.', {'entities': [(77, 105, 'Illumina assay')]}),
 ("All genome-wide SNP genotyping for the discovery cohorts was performed using the Illumina HumanHap550 BeadChip at the Center for Applied Genomics at the Children's Hospital of Philadelphia.", {'entities': [(81, 110, 'Illumina assay')]}),
 ('The Illumina Sentrix HumanHap550v3 genotyping BeadChips were used.', {'entities': [(4, 55, 'Illumina assay')]}),
 ('Genotyping was performed by the Center for Inherited Disease Research (CIDR) at John Hopkins University using the Illumina Infinium II assay protocol protocol [] for hybridization to Illumina HumanHap 1M BeadChips (Illumina, San Diego, CA).', {'entities': [(114, 213, 'Illumina assay')]}),
 (' Genotyping was done using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm ().', {'entities': [(31, 69, 'Affymetrix assay')]}),
 (' Both Leeds1 and Leeds2 case-control sample were supplemented with genotyping information from the Wellcome Trust Case-Control Consortium (WTCCC) 1958 birth cohort control samples analysed on the Illumina 550k array.', {'entities': [(196, 215, 'Illumina assay')]}),
 ('SNP genotyping was conducted using the Affymetrix Genome-wide Human SNP Array 5.0 and quality control was performed, both as previously described [].', {'entities': [(39, 81, 'Affymetrix assay')]}),
 (' DNA from AAs was genotyped on the Illumina Hum1M Beadarray.', {'entities': [(35, 59, 'Illumina assay')]}),
 ('org/) in each of the 96-well plates for Affymetrix SNP Array 6.0 genotyping.', {'entities': [(40, 64, 'Affymetrix assay')]}),
 (' Therefore, we expect genome coverage with the Affymetrix 500K set in this study to be similar to that estimated for the HapMap CEU panel.', {'entities': [(47, 62, 'Affymetrix assay')]}),
 (' Genotyping was performed using the Illumina 370 CNV BeadChip system.', {'entities': [(36, 61, 'Illumina assay')]}),
 ('Genome-wide genotyping was performed at Affymetrix on the Affymetrix 6.0 array with 2\xa0μg of DNA at a concentration of 100\xa0ng/μl.', {'entities': [(40, 78, 'Affymetrix assay')]}),
 (' Genotyping was performed in the BLSA sample with the 550k Illumina platform, and in the SardiNIA sample with the 10K and 500K Affymetrix mapping array set (see below and previous reports for additional information)(, ).', {'entities': [(59, 76, 'Illumina assay'), (127, 151, 'Affymetrix assay')]}),
 (' In total, we evaluated a total of 736,996 autosomal SNPs (651,201 from the Affymetrix array and 85,795 non-overlapping SNPs from the Immunochip) for association with the AbPA response to AVA.', {'entities': [(76, 92, 'Affymetrix assay')]}),
 (' In the genomewide association study, we determined the genotypes of patients with vitiligo for approximately 610,000 markers by using the Illumina 610-Quad BeadChip.', {'entities': [(139, 165, 'Illumina assay')]}),
 ('5) patients with idiopathic biopsy-proven FSGS and no family history of FSGS using the Illumina 1M-Duo platform.', {'entities': [(87, 111, 'Illumina assay')]}),
 ('html), adapted for Affymetrix 6.0 SNP data (,).', {'entities': []}),
 (" All participants were genotyped on the Affymetrix 6.0 platform; additional details about the height consortium are described in N'Diaye et al .", {'entities': [(40, 63, 'Affymetrix assay')]}),
 (' GWAS SNPs were genotyped using Illumina HumanCNV370-Quad v3.0 BeadChips on the Illumina BeadStation 500GX platform.', {'entities': [(32, 115, 'Illumina assay')]}),
 (' Forty-seven samples were initially genotyped on the Illumina Infinium 610-Quad, followed by an additional 40 samples (including 8 duplicates) on the 660-Quad.', {'entities': []}),
 ('Of the 1,303 AVA000 participants randomized to AVA-containing regimens, 1,070 individuals were genotyped (sample call rate > 95%, 1 sample excluded) using the Affymetrix Genome-Wide 6.0 array (Affymetrix Inc.', {'entities': [(159, 191, 'Affymetrix assay')]}),
 ("  In the discovery stage, we conducted the genotyping using Illumina Human 610-Quad Beadchips and the infiniumII assay following manufacturer's instructions.", {'entities': [(60, 93, 'Illumina assay')]}),
 (' For the pooled DNA analysis, the Affymetrix 100K SNP microarray (https://www.', {'entities': [(34, 64, 'Affymetrix assay')]}),
 (" Genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system.", {'entities': [(128, 152, 'Illumina assay')]}),
 (' For the present study, Illumina CNV370-Quadv3 GWAS data were available on 4241 individuals (including most alcohol dependent cases) genotyped at CIDR and an additional 2611 individuals genotyped by deCODE for the OZALC project; Illumina 317K data were available for 53 individuals genotyped at the University of Helsinki Genome Center; and Illumina 610 Quad data were available for the remaining individuals genotyped by deCODE.', {'entities': [(229, 242, 'Illumina assay')]}),
 (' In all, 390619 (380408 autosomal, 10211 X-chromosomal) markers overlapping between the 500\u2009K Affymetrix GeneChip and the Affymetrix Genome-Wide Human SNP Array 6.0 were included in the analyses.', {'entities': [(94, 164, 'Affymetrix assay')]}),
 ('For Illumina BeadChip genotyping, preliminary SNP quality control was assessed by the genotyping service provider, including call frequency (< 0.98), cluster separation (< 0.', {'entities': [(4, 21, 'Illumina assay')]}),
 (' Genotyping for discovery cohorts was centrally performed on the Illumina Human 610quad BeadChip at the Centre National de Génotypage (CNG, Evry, France).', {'entities': [(65, 96, 'Illumina assay')]}),
 ('We initially performed genotyping in a nested case-control study of postmenopausal invasive breast cancer within the NHS cohort () using the Illumina HumanHap550 array, as part of the National Cancer Institute’s Cancer Genetic Markers of Susceptibility (CGEMS) Project ().', {'entities': [(141, 167, 'Illumina assay')]}),
 ('MBCFS and MAY samples were genotyped at the Mayo Clinic Genotyping Shared Resource on the Illumina HumanHap 660W Quad and Illumina 610K arrays, respectively.', {'entities': [(90, 142, 'Illumina assay')]}),
 (' Additionally, all markers were re-genotyped on >10% of samples typed with the Illumina platform resulting in an observed mismatch in <0.5% of samples.', {'entities': [(79, 96, 'Illumina assay')]}),
 ('DNA was extracted and genotyped for consenting FHS participants with the Affymetrix 500K array and an additional gene-focused 50K array as part of the SNP Health Association Resource (SHARe) project with final genotypes available from 8482 participants.', {'entities': [(73, 94, 'Affymetrix assay')]}),
 (' SNPs were called using commercial software (Illumina GenomeStudio, v2011.1; Illumina, Inc.', {'entities': []}),
 (' The Illumina 370CNV BeadChip array was genotyped on 3664 participants.', {'entities': [(5, 29, 'Illumina assay')]}),
 ('2M chip as part of a separate WTCCC2 project, and the 50,000 SNPs which are shared between that platform and the Affymetrix 6.0 (used in this study) were used to evaluate genotype accuracy.', {'entities': []}),
 ('6 million genome-wide SNPs were genotyped in this DNA for each LCL using Illumina Infinium HumanHap 550K and 510S Bead Chips and Affymetrix 6.0 GeneChips.', {'entities': [(73, 124, 'Illumina assay')]}),
 ('All 484 subjects with multiple sclerosis were typed for 553 139 SNPs using the Illumina 550k platform with < 2% of genotyping failure rate per sample ().', {'entities': [(79, 101, 'Illumina assay')]}),
 ("  We first genotyped the whole-genome SNPs of 425 case and 301 control samples on an Affymetrix GeneChip Mapping 500K Array Set, following the manufacturer's instructions.", {'entities': [(85, 123, 'Affymetrix assay')]}),
 ('Variants reaching genome-wide significance (p < 5\xa0× 10_−8 ) in the discovery set were tested for association with PH in the Mayo Genome Consortia (MayoGC), which includes Mayo Clinic patients with both EMR and GWAS data derived from prior studies on Illumina HumanHap550, Human610-Quad, and Human660W-Quad platforms.', {'entities': [(250, 315, 'Illumina assay')]}),
 (' In brief, approximately half the sample was genotyped on the Affymetrix Human Mapping 500k Array Set, and the other half was genotyped using the Affymetrix Genome-Wide Human Array 5.0.', {'entities': [(62, 184, 'Affymetrix assay')]}),
 (' Genomic DNA samples were genotyped primarily using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(56, 98, 'Affymetrix assay')]}),
 (' DNA samples from the BTNS were genotyped by the Scientific Services Division at deCODE Genetics, Iceland, with the use of the Illumina 610-Quad BeadChip; genotypes were called with the Illumina BeadStudio software.', {'entities': [(127, 153, 'Illumina assay')]}),
 ('DNA samples used in the current study were part of several different projects focused primarily on the genetics of nicotine and alcohol addiction, collected in accordance with standard protocols and were drawn from 5 of 10 Illumina GWAS subsamples (N = 19,257 individuals) genotyped from the Genetic Epidemiology laboratory at QIMR.', {'entities': []}),
 (' Of the 545 patients, 316 cases and 229 controls were genotyped using the Affymetrix 500K SNP array (443,816 SNPs).', {'entities': [(74, 99, 'Affymetrix assay')]}),
 ('In Stage 1, using the 500K Affymetrix SNP array, 443,816 SNPs were analyzed.', {'entities': [(27, 47, 'Affymetrix assay')]}),
 (' All studies were genotyped with various versions of Illumina arrays, except GC-HBOC which was performed with the Affymetrix 5.0 (cases) and 6.', {'entities': [(53, 68, 'Illumina assay')]}),
 (' Individuals were genotyped on the Affymetrix 6.0 GeneChip Array.', {'entities': [(35, 64, 'Affymetrix assay')]}),
 (' Illumina Infinium II 550K SNP Chips (Illumina, Inc, San Diego, Calif) were genotyped in 422 nuclear families.', {'entities': [(1, 36, 'Illumina assay')]}),
 (' Genotyping was done using the Affymetrix Genome-Wide Human 6.0 Array (Santa Clara, CA, USA).', {'entities': [(31, 69, 'Affymetrix assay')]}),
 ('Genotyping for the 574 phase 1 breast cancer cases was conducted using the Illumina 660-Quad SNP array.', {'entities': [(75, 102, 'Illumina assay')]}),
 (' Genotyping was performed using the Illumina Infinium II assay protocol () with hybridization to Illumina HumanHap1M BeadChips (Illumina, San Diego, CA, USA), which contain 1,199,187 markers with a mean spacing of 2.4 kb.', {'entities': [(36, 126, 'Illumina assay')]}),
 (' Here, we present analyses using a subset of African American individuals in eMERGE who were genotyped on the Illumina 1M‐Duo (1M) (Illumina, San Diego, CA, USA) genotyping platform, a chip which includes many SNPs targeting variation in individuals of recent African descent.', {'entities': [(110, 181, 'Illumina assay')]}),
 (' The transcriptome-wide expression levels in two human primary cells (brain and PBMC) in the Duke samples () were assessed using Affymetrix Human ST 1.0 exon arrays.', {'entities': [(129, 164, 'Affymetrix assay')]}),
 (' Existing data from two sets of controls, genotyped on the Infinium 550k array, were used in stage 1 analyses: the Welcome Trust Case-Control Consortium 1958 birth cohort , and a national colorectal control study using Illumina platform Hap550 array.', {'entities': [(219, 236, 'Illumina assay')]}),
 (' Genotyping was conducted using the Illumina 550K array among self-reported Caucasian individuals, and succeeded in 6240 individuals (sample call rate ≥ 97.5%).', {'entities': [(36, 55, 'Illumina assay')]}),
 (' The Mayo PGRN study contributed data only for those 104 SNPs which were directly genotyped on the Illumina 610K platform.', {'entities': [(99, 121, 'Illumina assay')]}),
 ('  The primary scan for the discovery population of RCC case–control study (910 cases and 566 controls) was performed at MD Anderson Cancer Center using the Illumina HumanHap660W Beadchips.', {'entities': [(156, 187, 'Illumina assay')]}),
 ('We genotyped cases in the first phase of the study on the Illumina 370K chip.', {'entities': [(58, 76, 'Illumina assay')]}),
 (' In addition, a subset of MARIE cases (n  = 52) was genotyped using the Illumina CNV370 SNP array.', {'entities': [(72, 97, 'Illumina assay')]}),
 (' The nonsynonymous SNP, SLCO1B1  T521C (rs4149056) was not represented on the Affymetrix arrays and was independently genotyped (DNAPrint Genomics, Sarasota, FL); call rates were more than 97% for this SNP.', {'entities': [(78, 95, 'Affymetrix assay')]}),
 (' CGEMS is based on 1,145 cases and 1,142 controls drawn from the Nurses Health Study (see URLs) which were genotyped using the Illumina 550k array.', {'entities': [(127, 146, 'Illumina assay')]}),
 (' If the original candidate SNP was not genotyped on our array, we evaluated the imputed genotype, which was obtained by imputing all the HapMap release 22 SNPs (combined panel of ethnic groups: CEU [Utah residents with Northern and Western European ancestry from the CEPH collection], YRI [Yoruba in Ibadan], CHB [Han Chinese in Beijing], and JPT [Japanese in Tokyo]) that were not genotyped on the Affymetrix 5.0 array using IMPUTE software (https://mathgen.', {'entities': [(399, 419, 'Affymetrix assay')]}),
 (' Imputed genotypes were not determined in ARIC individuals of African ancestry and genotypes available for analysis were restricted to successfully genotyped SNPs on the Affymetrix 6.0 chip.', {'entities': [(170, 189, 'Affymetrix assay')]}),
 ('Participants of the HAPI Heart Study were genotyped with the use of the Affymetrix GeneChip® Human Mapping 500K Array set.', {'entities': [(72, 117, 'Affymetrix assay')]}),
 (' Each sample was genotyped with the Affymetrix GeneChip Human Mapping 100\u2009K array pair (Santa Clara, CA, USA), as described in the GeneChip Human Mapping 100\u2009K Assay Manual.', {'entities': [(36, 81, 'Affymetrix assay')]}),
 (' All cases were genotyped with the Illumina Human 610Quad platform.', {'entities': [(35, 66, 'Illumina assay')]}),
 (' Finally control data were available from two further groups: French controls from CNG genotyped on the Illumina HumanHap300 BeadChip version 2 duo array and UK controls from the WTCCC (described in  but based for this analysis on Illumina HumanHap300 BeadChip version 2 duo array genotyping).', {'entities': [(104, 133, 'Illumina assay')]}),
 (' Affymetrix performed plate-based genotype calling using Birdseed v2. Sample QC was based on call rates and contrast QC (cQC) statistics.', {'entities': []}),
 ('0 (Reich Lab, Harvard University, MA, USA) were included as covariates in age, sex adjusted analyses for CoLaus, GEMs, NFBC, and LOLIPOP Indian Asian Illumina analyses (the number of principal components included varied from 4 to 10, depending on the population structure of the specific cohort).', {'entities': []}),
 (' All DNA samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute Biological Sample Repository (BSP) as a part of STAMPEED consortium funded by the US National Heart, Lung, and Blood Institute.', {'entities': [(25, 58, 'Illumina assay')]}),
 (' Controls for both the GAIN-BP and BiGS samples were ascertained throughout the United States and genotyped on the Affymetrix 6.0 array as part of the Molecular Genetics of Schizophrenia II (MGS2) Collaboration ().', {'entities': [(115, 135, 'Affymetrix assay')]}),
 ('  Genotyping information for rs872071 was taken from the Illumina 317K data generated for the GWAS.', {'entities': [(57, 70, 'Illumina assay')]}),
 ('981) failed Illumina scoring and were replaced with a highly correlated tag SNP (rs9268544, r_2  = 1.0 for both SNPs).', {'entities': []}),
 ('We used the Illumina Human-1 BeadChip.', {'entities': [(12, 37, 'Illumina assay')]}),
 (' Only SNPs included in the Affymetrix 6.0 SNP arrays were selected for Stage-II evaluation.', {'entities': [(27, 52, 'Affymetrix assay')]}),
 (' These are supplemented by 3878 controls from the WTCCC study [WTCCC ()] genotyped on the Illumina HumanHap1.2 million array and 1905 French controls genotyped by Centre National de Genotypage on the Illumina Humancnv370k array.', {'entities': [(90, 124, 'Illumina assay')]}),
 (' Cases were genotyped by Illumina (San Diego) on Illumina Omni1-Quad (568 AMFS cases, 699 Q-MEGA cases) and HumanHap610W Quad arrays (998 Q-MEGA cases).', {'entities': [(25, 132, 'Illumina assay')]}),
 (' Specifically, 1412 were genotyped with the 500K Affymetrix Mapping Array Set and 3,329 with the 10K Mapping Array Set, with 436 individuals genotyped with both arrays.', {'entities': [(49, 73, 'Affymetrix assay')]}),
 (' In all, 390 619 autosomal markers overlapping between the 500K Affymetrix GeneChip and the Affymetrix Genome-Wide Human SNP Array 6.0 were included in the analyses.', {'entities': [(64, 134, 'Affymetrix assay')]}),
 ('Genomic DNA samples (750 ng) isolated from RRNL cases (described above) were genotyped on the Illumina BeadStation 500GX following standard manufacturing protocols.', {'entities': []}),
 (' To compare the consistency between Affymetrix 6.0 and Sequenom platforms, we also genotyped 124 samples included in Stage I in the Stage II Sequenom genotyping; the concordance rate was 98.', {'entities': [(36, 73, 'Affymetrix assay')]}),
 (' Genotyping was performed using the Affymetrix 500K Mapping Array Set using the call algorithm CHIAMO as implemented by the WTCCC.', {'entities': [(36, 65, 'Affymetrix assay')]}),
 (' For the Leeds sample, genotyping data from the Illumina HumanHap300 v2 array were available for the 123 familial cases and for 148 cases and 167 controls (Leeds1 sample).', {'entities': [(48, 77, 'Illumina assay')]}),
 ('The DNA samples of the CSSCD, BMC, Hong Kong, and Duke subjects were genotyped with the Illumina Human610-Quad SNP array with approximately 600\u2009000 single nucleotide polymorphisms (SNPs) and covers approximately 60% of the genome of the HapMap Yoruban (r_2  > 0.8) and 18\u2009000 known genes.', {'entities': [(88, 120, 'Illumina assay')]}),
 (' Genotypes were determined using Illumina BeadStudio Genotyping Module version 3.2.', {'entities': []}),
 (' The London phase 1 GWA study was conducted using the Illumina HumanHap550 Bead Arrays, and the Edinburgh phase 1 GWA study was conducted using Illumina HumanHap300 and HumanHap240S according to the manufacturer’s protocols ( online).', {'entities': [(54, 86, 'Illumina assay')]}),
 (' We utilized controls from the 1958 Birth Cohort that had been previously genotyped on the Illumina 550K chip.', {'entities': [(91, 109, 'Illumina assay')]}),
 (' HEBCS cases (n  = 85) were genotyped using the Illumina 550 SNP array and population allele and genotype frequencies on healthy population controls (n  = 222) were genotyped on Illumina 370 SNP array, and obtained from the NordicDB, a Nordic pool and portal for genome-wide control data () from the Finnish Genome Center.', {'entities': [(48, 70, 'Illumina assay')]}),
 ('01 in the Maywood and the Nigerian cohorts, respectively, in addition to the directly genotyped SNPs on the Affymetrix 6.0 array.', {'entities': [(108, 128, 'Affymetrix assay')]}),
 ('   All adolescents (n  = 602) were genotyped with the Illumina Human610-Quad BeadChip (Illumina, Inc.', {'entities': [(54, 85, 'Illumina assay')]}),
 (' The Rotterdam study samples were genotyped by using the Illumina 550k arrays and the additional MARS samples using the Illumina 610k array.', {'entities': [(57, 77, 'Illumina assay')]}),
 (' Biotinylated cRNA was hybridized to the Affymetrix GeneChip HG-U133 Plus 2.0 arrays, containing probes for approximately 22,634 genes, at the CCHMC Digestive Health Center Microarray Core.', {'entities': [(41, 84, 'Affymetrix assay')]}),
 (' Briefly, 10 004 participants from the Ansung and Ansan cohorts were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(89, 131, 'Affymetrix assay')]}),
 ('  In an analysis of 1000 samples, the comparison of the Illumina calls with the TaqMan assays showed a concordance rate of 100%.', {'entities': []}),
 ('Single-nucleotide polymorphisms (SNPs) were genotyped at the Illumina Genotyping Service Center, San Diego, California, using Illumina HumanHap 650Y chips.', {'entities': [(61, 154, 'Illumina assay')]}),
 (' Allele cluster definitions for each SNP were determined using Illumina BeadStudio Genotyping Module version 3.1.', {'entities': []}),
 (' Genotyping was performed using the Affymetrix GeneChip® Human Mapping 500K array set, as recommended by the manufacturer.', {'entities': [(36, 81, 'Affymetrix assay')]}),
 ('  DNA was genotyped with the Illumina Human660W-Quad BeadChip, and 494,082 SNPs passed quality control filters (sample call rate > 98%, SNP call rate > 95%, minor allele frequency > 5%, Hardy–Weinberg disequilibrium P  < 1 × 10_−6 ) and were merged with Hapmap European reference populations; 599 individuals were removed as genetic outliers based on PCA of an allele-sharing distance matrix.', {'entities': [(29, 61, 'Illumina assay')]}),
 ('  A total of 459 Caucasian individuals with severe mental disorders and 313 healthy controls were recruited and successfully genotyped on Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix Inc.', {'entities': [(138, 180, 'Affymetrix assay')]}),
 (' Genotyping of Rotterdam subjects was conducted with the Illumina HumanHap550K array on 5974 participants.', {'entities': [(57, 84, 'Illumina assay')]}),
 (' We used the Affymetrix Genome-Wide Human SNP Array 6.0 to obtain genotypes for the NSHL cases and GAIN controls.', {'entities': [(13, 55, 'Affymetrix assay')]}),
 (' Genotypes were assayed using the Affymetrix Genome-Wide Human SNP Array 6.0 platform, and genotypes were called using the Birdseed algorithm.', {'entities': [(34, 76, 'Affymetrix assay')]}),
 (' Participants’ DNA was extracted from blood samples drawn from an antecubital vein, and genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 6.0 chip.', {'entities': [(122, 169, 'Affymetrix assay')]}),
 ('5μg of genomic DNA (15μl of 100ng/μl stock) with the Illumina Infinium II HumanHap 300 BeadChips (Illumina, San Diego, CA) at Cedars-Sinai Medical Center using standardized protocol[].', {'entities': [(53, 96, 'Illumina assay')]}),
 ('Genome-wide genotyping of single nucleotide polymorphisms (SNPs) was performed on the Affymetrix Genome-Wide Human Array 6.0 chip in a subset of European ancestry patients in GeneBank.', {'entities': [(86, 129, 'Affymetrix assay')]}),
 (' Genotyping was performed at the Center for Inherited Disease Research using 1 μg of genomic DNA (diluted in 1× TE buffer and at 50 ng/μl) on Affymetrix Genome-Wide Human SNP array 6.0.', {'entities': [(142, 184, 'Affymetrix assay')]}),
 ('Genome-wide genotyping was performed using Illumina Human Hap550K chips.', {'entities': [(43, 71, 'Illumina assay')]}),
 ('  Genotypes were assayed using the Affymetrix Genome-Wide Human SNP Array 6.0 platform, and genotypes were called using the Birdseed algorithm.', {'entities': [(35, 77, 'Affymetrix assay')]}),
 (' DNA extracted from the baseline blood samples underwent SNP genotyping using the Illumina Infinium II assay to query a genome-wide set of 315,176 haplotype-tagging SNP markers (Human HAP300 panel) as well as a focused panel of 45,882 missense and haplotype tagging SNPs selected to enhance coverage of genomic regions in which we had a strong a priori  interest owing to presence of genes believed to be of relevance to metabolic, cardiovascular, and inflammatory diseases.', {'entities': []}),
 (' Genotype data were then assessed using the Genotyping Module of Illumina’s BeadStudio software (version 2.0).', {'entities': []}),
 (' Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array, version 6.0.', {'entities': [(36, 74, 'Affymetrix assay')]}),
 (' The genotyping data from 166 of 277 LCLs using Illumina HumanHap 550K BeadChips had been used in a previous study ().', {'entities': [(48, 80, 'Illumina assay')]}),
 (' Genotyping was completed on the Illumina Human1M and Human1M-Duo Bead Array in accordance with the manufacturer’s protocol.', {'entities': [(33, 76, 'Illumina assay')]}),
 (' All assays used the Affymetrix GeneChip Genome-Wide Human SNP Array 5.0, with hybridization and scanning at the ASL.', {'entities': [(21, 72, 'Affymetrix assay')]}),
 (' The controls had been genotyped using Illumina HumanHap550 Bead Chips.', {'entities': [(39, 70, 'Illumina assay')]}),
 (' Genotypes on the Illumina platform were called using GenCall algorithm as implemented in GenomeStudio version 2009.1 (Illumina, Inc.', {'entities': [(18, 35, 'Illumina assay')]}),
 (" Genotype calls were made using the auto-calling algorithm in Illumina's BeadStudio 2.0 software.", {'entities': []}),
 (' The data retrieved from IntraGen Population Genetics Database (IntraGenDB) consisted of 478 individuals between the ages of 30 and 60, of non-Jewish white ancestry, genotyped with the Illumina HumanHap300 genotyping platform.', {'entities': [(185, 225, 'Illumina assay')]}),
 (' The EADI1 used the Illumina Quad 6.0 and GERAD1 was genotyped on various Illumina chips.', {'entities': [(20, 88, 'Illumina assay')]}),
 (' The probe detection level was assessed with the use of Illumina’s detection P  value, where at least 18 of the 35 samples were required to have a detection of P  less than .', {'entities': []}),
 ('ADNI participants and approximately two-thirds of the MIRAGE subjects were genotyped on the Illumina Infinium Human 610-Quad BeadChip.', {'entities': [(92, 133, 'Illumina assay')]}),
 (' Individuals were genotypied on the Illumina HumanHap650Y versions 1 and 3 BeadChips (Illumina, Inc.', {'entities': [(36, 84, 'Illumina assay')]}),
 (' In the two Canadian cohorts, rs321588, rs7751374, rs10124954, and rs6499255 were genotyped on the Illumina Human610-Quad array; rs9469220, rs537526, and rs16977747 were imputed using MACH; rs2885872 was a genotyped proxy (CEU r_2 =1.0) used for rs2363709; and rs10043454 and rs4355582 were imputed proxies used for rs13361473 and rs10944017, respectively.', {'entities': [(99, 127, 'Illumina assay')]}),
 ('  Genotyping was conducted using the Affymetrix 500K mapping array and the Affymetrix 50K gene-focused macrophage inflammatory protein array.', {'entities': [(37, 66, 'Affymetrix assay')]}),
 (' For the African Caribbean Version 3 sample set, allele cluster definitions were determined using the combined intensity data from 96 study samples and HapMap controls genotyped together, plus 120 HapMap samples genotyped at Illumina using BeadStudio Genotyping Module (Version 3.1.', {'entities': []}),
 ('DNA preparation, genome-wide genotyping using the Illumina 610-Quad BeadChip (Illumina, San Diego, CA) and replication genotyping using the Sequnom MassArray iPLEX system (Sequenom, San Diego, CA), and quality control filtering of the data have been described previously ().', {'entities': [(50, 76, 'Illumina assay')]}),
 (' Initially, 77% of the samples were genotyped on the Illumina HumanCNV370-Duo_v1 array (370,404 SNPs), and 23% of the samples on the Illumina HumanCNV370-Duo_v3 array (373,398 SNPs).', {'entities': [(53, 86, 'Illumina assay')]}),
 (' Controls had been genotyped previously using the Affymetrix® Genome-Wide Human SNP Array 6.0 platform and had passed genotyping quality controls measures analogous to those used for TGCT cases (see below).', {'entities': [(50, 93, 'Affymetrix assay')]}),
 (' DNA was isolated using the protocol described by DNA Genotek, and SNP genotyping was performed using the Illumina HumanCNV370 BeadChip.', {'entities': [(106, 135, 'Illumina assay')]}),
 ('1 locus, we examined the association statistics for these markers in a third independently generated and analysed cohort, including 1,390 subjects from 447 autism families genotyped with ~1 million markers on the Illumina HumanHap1M BeadChip (CAP cohort, ).', {'entities': [(213, 241, 'Illumina assay')]}),
 (' GWAS of breast cancer in Latino (MEC-LAT) and Japanese (MEC-JPT) samples from the MEC were genotyped with the Illumina 660W array at USC.', {'entities': [(111, 130, 'Illumina assay')]}),
 ('Of the 726 European-Americans included in the GWAS analysis, 671 (due to sample availability) were also genotyped on the Immunochip, a custom Illumina Infinium array (196,524 SNPs) designed for replication and fine mapping of established GWAS loci and strong candidate genes for autoimmune and inflammatory diseases [].', {'entities': [(142, 165, 'Illumina assay')]}),
 (' The QIMR participants analyzed here were genotyped on the Illumina Human610-Quad SNP chip.', {'entities': [(59, 90, 'Illumina assay')]}),
 (' Only SNPs that were present on each of the three genotyping platforms (Illumina 550v1, 550v3 and 610) were included in the genetic association testing (n  = 535 752).', {'entities': []}),
 (' For SNP quality assurance, we repeated the genotyping of 471,000 SNPs for 151 individuals with use of the Affymetrix Genome-Wide Human SNP Array (version 6.0; J.', {'entities': [(107, 145, 'Affymetrix assay')]}),
 (' Seven hundred and seventy-five African-Americans from Maywood, IL, were genotyped with Affymetrix Genome-wide human SNP array 6.0, which provided genotype data at 909 622 SNPs in the human genome.', {'entities': [(88, 130, 'Affymetrix assay')]}),
 (' These had been genotyped on the Illumina HumanHap 550v2. All samples were confirmed to be of European ancestry by principal component analysis with ancestry informative markers.', {'entities': []}),
 (' Finally for the NARAC-III cases (unpublished data) and shared controls, we used available Illumina 317K GWA data for 269,771 SNPs passing stringent quality control criteria.', {'entities': [(91, 104, 'Illumina assay')]}),
 ('GWAS of the CAPS population was performed using Affymetrix 5.0 chip.', {'entities': [(48, 67, 'Affymetrix assay')]}),
 ('Genotyping was performed in FHS by Affymetrix (Santa Clara, CA), using the Affymetrix 500K GeneChip array and a custom-designed gene-centric 50K molecular inversion probe, according to an established methodology ().', {'entities': [(35, 105, 'Affymetrix assay')]}),
 (' Out of the 5110 coffee drinkers, 2680 have been genotyped on a chip containing the Illumina 317K set of SNPs in one of several genome-wide association studies conducted by deCODE Genetics.', {'entities': [(84, 97, 'Illumina assay')]}),
 ('Genotyping was performed in HAPI Heart Study participants with the Affymetrix GeneChip Human Mapping 500 K Array set (Affymetrix, Santa Clara, CA, USA), including a total of 500 568 single nucleotide polymorphisms (SNPs).', {'entities': [(67, 112, 'Affymetrix assay')]}),
 (' For the Molecular Genetics of Schizophrenia (MGS2) genome wide association study (GWAS) of schizophrenia (), we genotyped 3,827 (2,817 EA and 1,010 AA) control samples with the Affymetrix 6.0 array, selected for eligibility based on previous laboratory study of genotypic ancestral background and DNA quality.', {'entities': [(178, 198, 'Affymetrix assay')]}),
 ('Genotyping was conducted using an Illumina HumanOmniExpress BeadChip system (729,755; single nucleotide polymorphisms [SNPs] included) at the Center for Cancer Genomics, Wake Forest University School of Medicine.', {'entities': [(34, 68, 'Illumina assay')]}),
 (' We included all MESA participants who underwent GWAS genotying using the Affymetrix 6.0 SNP array as part of the MESA SNP Health Association Resource (SHARe) (study accession phs000209, http://www.', {'entities': [(74, 98, 'Affymetrix assay')]}),
 (' Genotyping was performed using the Affymetrix 500K (GerMIFS1) and 6.0 (GerMIFS2, PennCath, MedStar, OHGS_CCGB_S) arrays.', {'entities': [(36, 120, 'Affymetrix assay')]}),
 (' In brief, total RNA was isolated from monocytes of 1,606 participants of the GHSExpress Study and hybridized to Illumina HT-12 v3 BeadChips (Illumina Inc.', {'entities': [(113, 140, 'Illumina assay')]}),
 ('A GWA analysis for 815 children was conducted using single nucleotide polymorphism (SNP) assays included on the Illumina HumanOmni1-Quad v1.0 BeadChips (Illumina, San Diego, CA).', {'entities': [(112, 151, 'Illumina assay')]}),
 (' Publicly available Affymetrix SNP Array 6.0 Chip SNP data were also obtained for the same cell lines.', {'entities': [(20, 49, 'Affymetrix assay')]}),
 (' Genotypes were called using Birdseed version 2; Affymetrix Power Tools (APT) 1.10.', {'entities': []}),
 (' Whole genome genotyping was performed using the Affymetrix Genechip® Human Mapping 500K Array Set, which included 238,304 SNPs from a StyI  chip and 262,264 SNPs from an NspI  chip.', {'entities': [(49, 145, 'Affymetrix assay')]}),
 (' Genotyping for the replication set was performed using Illumina BeadXpress 384-plex on the 1,374 subjects.', {'entities': []}),
 (" Samples that passed the above exclusion criteria were genotyped using Illumina's Human 1Mv1 Beadchip, containing 1,072,820 SNPs (of those 258,665 loci are in reported and new CNV regions).", {'entities': [(71, 101, 'Illumina assay')]}),
 (' The Illumina HumanHap550v3 Genotyping BeadChip was used to genotype >550,000 SNPs in these samples.', {'entities': [(5, 47, 'Illumina assay')]}),
 (' CAPS samples were genotyped using the Affymetrix 500k gene chip.', {'entities': [(39, 64, 'Affymetrix assay')]}),
 (' Genotyping of a genome-wide set of 1,054,559 SNPs was performed using the Illumina Infinium II Human 1M bead chip at two national centres (Centre National de Génotypage, Paris, France and the SNP Technology Platform, Uppsala, Sweden).', {'entities': [(75, 216, 'Illumina assay')]}),
 (" We performed genotyping in BC_NHS, using the Illumina HumanHap550 array, as part of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) Project ().", {'entities': [(46, 72, 'Illumina assay')]}),
 ('A custom Illumina genotyping array was designed with 768 SNPs that included: Known causative mutations:  SNPs that genotyped two common LRRK2  mutations in European populations (G2019S and R1441H); Known risk factors: GBA  (N370S, L444P, E326K, T369M); Previous GWAS associations: PARK16 , LRRK2 _, , SNCA , MAPT _– , GAK _, , the HLA region; Sex confirmation:  3 SNPs on the Y chromosome and 6 SNPs on the X chromosome in addition to the sex-specific probes included in the GoldenGate custom oligonucleotide pool; Top priority association results from the meta-analysis:  SNPs were selected based on increasing p-value.', {'entities': [(9, 34, 'Illumina assay')]}),
 (' The Illumina HumanHap300 Genotyping BeadChip comprises about 317,000 SNPs.', {'entities': [(5, 45, 'Illumina assay')]}),
 (' (i) The genotyping for the KS_NHS_HPFS was performed using the Illumina HumanHap610 Quad, and the imputation was performed in the same fashion as in the discovery set.', {'entities': []}),
 (' DNA samples for the first-stage GWAS were genotyped with use of the Illumina HumanOmni1-Quad_v1-0_B array and were called using the BeadStudio algorithm, at the John Hopkins University Center for Inherited Disease Research (CIDR).', {'entities': [(69, 106, 'Illumina assay')]}),
 ('5% HapMap mismatch), and additional control data used the Illumina Infinium 317K and HumanCNV370-duo Bead Arrays; per-SNP call rate was >97%, and concordance was >98.5%.', {'entities': [(58, 112, 'Illumina assay')]}),
 (' Genotyping of the samples in the discovery cohorts (RS-I and RS-II) was carried out with the Illumina HumanHap 550v3 Genotyping BeadChip.', {'entities': [(94, 137, 'Illumina assay')]}),
 (' Genotyping with the Affymetrix Mapping 250K Nsp and 250K Sty arrays was performed using the standard protocol recommended by the manufacturer.', {'entities': [(21, 68, 'Affymetrix assay')]}),
 (' We used a BF >3 to select significant SNPs in genes based on the following consideration: The mean number of SNPs per gene in the Illumina 610 is 25, and because the decision rule to accept an association as significant if the BF >3 has a false positive rate of about 2%, the expected number of false positive single SNP association per gene is on average 5%.', {'entities': []}),
 (' CGEMS and Illumina iControlDB controls were genotyped on Illumina Hap550K-BeadChip.', {'entities': [(11, 83, 'Illumina assay')]}),
 (' To seek further evidence of replication, we examined association statistics from a fourth independent cohort of 108 ASD cases and 540 genetically matched control subjects, genotyped on the Illumina HumanCNV370 BeadChip, an array with over 300,000 SNP markers (CART cohort, ).', {'entities': [(190, 219, 'Illumina assay')]}),
 (' Genotype calling was performed using the BRLMM algorithm of the Affymetrix GeneChip Genotyping Analysis Software (GTYPE) version 4.1.', {'entities': []}),
 (' All subjects were genotyped using the Illumina Human1M-Duo BeadChip, containing 1,072,820 markers.', {'entities': [(39, 68, 'Illumina assay')]}),
 (' Genome-wide genotyping was performed using Illumina Human Hap550K chip.', {'entities': [(44, 71, 'Illumina assay')]}),
 (' The replication samples from NHS were genotyped at Rosetta/Merck using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm ().', {'entities': [(76, 114, 'Affymetrix assay')]}),
 (' For ERF, DNA was genotyped with one of four different platforms (Illumina 6K, Illumina 318K, Illumina 370K, and Affymetrix 250K).', {'entities': [(66, 77, 'Illumina assay'), (113, 128, 'Affymetrix assay')]}),
 ('0 software to impute SNPs that are not covered in Affymetrix 6.0 chip.', {'entities': [(50, 69, 'Affymetrix assay')]}),
 (' GWAS data for public controls (n  = 3448) were generated using the following arrays: Illumina 660-Quad SNP array (QIMR), Illumina 550 SNP array (CGEMS), Illumina 550 SNP array (KORA) and Illumina 1.2M (WTCCC).', {'entities': [(86, 113, 'Illumina assay')]}),
 (' The remaining MIRAGE subjects were genotyped with the Illumina Infinium HUmanCNV370-Duo BeadChip.', {'entities': [(55, 97, 'Illumina assay')]}),
 (' The subjects were genotyped on the Illumina 1M version 1 BeadChip.', {'entities': [(36, 66, 'Illumina assay')]}),
 (' Genotyping for 59 patients in the validation cohort was performed by using the Affymetrix Genome-Wide Human SNP Array 6.0 based on the Birdseed genotype-calling algorithm, which overlaps with 482,251 of the 500,568 SNPs on the 500K chip.', {'entities': [(80, 237, 'Affymetrix assay')]}),
 (' Genotyping was conducted on the Affymetrix Genome-Wide Human SNP 6.0 Array; quality control on sample and SNP level was performed according to standardized criteria.', {'entities': [(33, 75, 'Affymetrix assay')]}),
 (' The Affymetrix HG-U133A 2.0 Array (Affymetrix Inc, Santa Clara, CA, USA), comprising more than 22,283 probe sets, was used to interrogate the expression of RNA as described.', {'entities': [(5, 34, 'Affymetrix assay')]}),
 ('SNP genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 5.0 at the Vanderbilt Microarray Shared Resource at Vanderbilt University Medical Center, Nashville, TN, USA, using the standard protocol recommended by the manufacturer.', {'entities': [(38, 80, 'Affymetrix assay')]}),
 (' Data from the SeBCS phase I (SeBCS-I) analyzed in Stage IV were extracted from GWA scan data generated using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(114, 156, 'Affymetrix assay')]}),
 (' CGEMS included 2277 samples (1101 controls and 1176 cases) genotyped for 546,613 SNPs using the Illumina 317K and 240K arrays.', {'entities': [(97, 126, 'Illumina assay')]}),
 (' Of the 14,612 SNPs submitted to Illumina from 764 genes within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways, 1,585 SNPs (covering 1,100 LD bins) failed manufacture, leaving 13,027 successfully genotyped SNPs.', {'entities': []}),
 (' The concordance for the TaqMan genotyping data with that generated from Illumina for Stage 1 ER-negative cases and controls was 0.997 for rs17530068 and 0.', {'entities': []}),
 (' studies, all subjects had been genotyped on the Illumina 610k-Quad Beadchips.', {'entities': [(49, 77, 'Illumina assay')]}),
 (' Briefly, genotyping was performed on 11,766 of the 38,418 individuals through five separate genotyping projects on a combination of Illumina 317K, Illumina 370K, and Illumina 610K microarray chips.', {'entities': [(133, 191, 'Illumina assay')]}),
 (' The DNA for 1458 subjects was genotyped using Illumina (San Diego, CA, USA) genotyping chips and single-nucleotide polymorphisms (SNPs) from the HumanH610 were used for analysis (Supplementary methods).', {'entities': [(47, 93, 'Illumina assay')]}),
 (' Genotyping was performed using the Affymetrix 6.0 array and genotypes were called using the Birdsees software.', {'entities': [(36, 56, 'Affymetrix assay')]}),
 (' The selected SNPs were extracted from a larger set of SNPs genotyped in 2,433 unique samples on a custom 10,640-bead iSelect array from Illumina designed for 7703 SNPs.', {'entities': []}),
 ('We used 393,453 SNPs from the Affymetrix GeneChip Human Mapping 500K platform, which was used in a recent report of type 2 diabetes association using the same WTCCC type 2 diabetes samples.', {'entities': [(30, 77, 'Affymetrix assay')]}),
 (' For polymorphic SNPs on the Affymetrix chip, we performed trend tests (1 degree of freedom) and general genotype tests (2 degrees of freedom, referred to as genotypic) between each case collection and the pooled controls, and calculated analogous Bayes factors.', {'entities': [(29, 44, 'Affymetrix assay')]}),
 (' These individuals were ascertained from the same QIMR studies that contributed data to the GWAS (Supplementary Table 2) and were recently typed with Illumina 610K arrays as part of an additional, as yet unpublished wave of genotyping conducted in the first semester of 2010. All samples are of European descent and passed the standard QC filters described above for the GWAS.', {'entities': [(150, 170, 'Illumina assay')]}),
 (' Briefly, samples were genotyped using Infinium II technology from Illumina (HumanHap300 Duo-Plus chip).', {'entities': [(67, 102, 'Illumina assay')]}),
 (' Within the Affymetrix 6.0 chip, there were 2906 duplicate SNPs, among which we observed > 99.', {'entities': [(12, 31, 'Affymetrix assay')]}),
 (' We have used the Illumina 1M and 1M-Duo bead chip data as input into the Penn CNV program [], which allows us to look at deletions (0, 1 copy) as compared to wild type (2 copies) and duplications (3, 4 copies) as compared to wild type (2 copies).', {'entities': [(18, 50, 'Illumina assay')]}),
 (' Expression data were collated and quality checked in the Illumina BeadStudio and then imported into GeneSpring V10.0 (Agilent Technologies, Santa Clara, CA, USA).', {'entities': []}),
 (' Genotyping was done using the Illumina Infinium II assay to query a genome-wide set of 315,176 haplotype-tagging SNP markers (Human HAP300 panel) as well as a focused panel of 45,882 missense and haplotype tagging SNPs.', {'entities': []}),
 (' We used 1641 unselected European American samples and 1827 unselected African American samples genotyped with the Illumina 550Kv3 platform from the iControldb database (http://www.', {'entities': [(115, 139, 'Illumina assay')]}),
 ('Genotypes were generated using Illumina’s HumanHap300 BeadChip (San Diego, CA) for the 1154 patients included in our previous genome-wide association studies of lung cancer risk ().', {'entities': [(31, 62, 'Illumina assay')]}),
 ('5 μg of genomic DNA (15 ul of 100 ng/ul stock) and the Illumina Infinium II HumanHap 300 BeadChips at Cedars-Sinai Medical Center using the Illumina Infinium II assay protocol [].', {'entities': [(55, 98, 'Illumina assay')]}),
 ('DNA from all of the LCLs was genotyped using Illumina HumanHap 550K and 510S BeadChips, which assayed 561,298 and 493,750 SNPs, respectively.', {'entities': [(45, 86, 'Illumina assay')]}),
 ('Genotyping was done using the Affymetrix Genome-Wide Human SNP Array 6.0 ().', {'entities': [(30, 72, 'Affymetrix assay')]}),
 (' We carried out genotyping for an additional 81 patients from MD Anderson Cancer Center using Illumina’s HumanHap317 BeadChip.', {'entities': [(94, 125, 'Illumina assay')]}),
 (' Briefly, genotyping was done using Affymetrix Genome-Wide Human 6.0 array and genotypes were called using the Birdseed algorithm for a total of 906,600 single nucleotide polymorphisms (SNPs) ().', {'entities': [(36, 74, 'Affymetrix assay')]}),
 (' The first replication case series was genotyped by Illumina Human610 BeadChip, yet two additional replication case series were genotyped by TaqMan.', {'entities': [(52, 78, 'Illumina assay')]}),
 ('Of the 116 201 SNPs on the Affymetrix GeneChip Human Mapping 100K array set, the number of SNPs suitable for statistical analysis was reduced to 102 334 in black subjects (88.0% of total) and to 95 221 in white subjects (81.', {'entities': [(27, 71, 'Affymetrix assay')]}),
 (' DNA was extracted from blood, quantitated and genotyped by using Affymetrix 6.0 microarrays according to the manufacturer’s instructions.', {'entities': [(66, 92, 'Affymetrix assay')]}),
 ('3 were retained, which resulted in a total number of 2,380,486 imputed Illumina and 2,369,130 imputed Affymetrix SNPs.', {'entities': []}),
 (' Using the SNP map annotations provided by Affymetrix 5.0 GeneChip as a reference (https://www.', {'entities': []}),
 ('05, Illumina GC scores of >0.8 and present in HapMap CEU subjects.', {'entities': []}),
 ('All of the subjects from four BPC3 cohorts (1239 cases and 1188 controls), most of the subjects from a fifth (656 cases and 409 controls) and cases from the two remaining cohorts (249 and 437) were genotyped specifically for this study using Illumina Human 610-Quad Beadchips (Illumina, Inc).', {'entities': [(242, 275, 'Illumina assay')]}),
 ('_,   Imputation with HLA*IMP is performed using pre-defined sets of SNPs for each of several common commercial microarrays, including the Affymetrix 500K and 6.0, but not the Axiom array.', {'entities': [(138, 186, 'Affymetrix assay')]}),
 ('All samples were genotyped on the Illumina Human 1M beadchip at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University (Baltimore, MD USA).', {'entities': [(34, 60, 'Illumina assay')]}),
 (' In total, 1,191 cases and 999 controls were successfully genotyped on the Illumina 1M/1M Duo platform and passed all quality-control (QC) steps.', {'entities': [(75, 102, 'Illumina assay')]}),
 (' All subjects were genotyped on the Illumina Human 1M beadchip.', {'entities': [(36, 62, 'Illumina assay')]}),
 (' Individual genotype data for 1494 participants were extracted from the genomewide array (Illumina 660 Quad Array).', {'entities': [(90, 113, 'Illumina assay')]})]